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The aim of this thesis was to explore the relation between visceral obesity and the accompany-
ing metabolic disturbances, systemic infl ammation and the atherosclerotic process. For this 
purpose, a newly developed magnetic resonance vessel wall imaging technique was imple-
mented in phenotyping patients and as a therapeutic endpoint in a randomised controlled set-
ting. This introductory chapter gives an overview of the background of the studies contained 
within this thesis.
CARDIOVASCULAR DISEASE AND ATHEROSCLEROSIS
Cardiovascular disease is the leading cause of morbidity and mortality worldwide with athero-
sclerosis as the primary underlying pathophysiological process.1, 2 Atherosclerosis is a progres-
sive disease characterized by the accumulation of lipids and fi brous elements in large arteries. 
The early stages of atherosclerosis is characterised by the accumulation of lipid-engorged 
macrophages beneath the endothelium.3, 4 These early atherosclerotic lesions also known as 
fatty streaks are not clinically relevant and can be seen in various vascular beds from an early 
age.5 Fatty streaks may progress into more advanced lesions known as atherosclerotic plaques, 
which are characterized by the accumulation of lipid-rich necrotic debris and smooth muscle 
cells.6 Although advanced plaques can grow suffi  ciently large to disrupt blood fl ow, the current 
evidence suggests that the main cause of cardiovascular events is a sudden expansion of the 
atheromatous plaque as a result of thrombosis in response to the physical disruption of the 
plaque integrity.7, 8 Three types of physical disruption may occur resulting into the instability of 
the plaque namely: ulceration at the luminal surface9, haemorrhage from the small vessels that 
grow into the lesion from the media of the blood vessel10, and fi nally the most common mecha-
nism of plaque disruption, a fracture of the plaque’s fi brous cap.11 Epidemiological studies have 
revealed numerous risk factors for the development and progression of atherosclerosis.12-15 
These can be grouped into factors with an important genetic component (gender, hyperten-
sion, diabetes and obesity, and familial dyslipidemias), and those that are largely environmental 
such as smoking, high-fat diet and lack of exercise. These traditional risk factors are used in the 
clinical setting to estimate the risk of future cardiovascular disease. This clinical use of the risk 
factors is however complicated by the presence of interactions between risk factors. As a result, 
the risk factors are not simply additive, and their eff ect might considerably be modifi ed by the 
presence or absence of other risk factors. 
The recent increase in cardiovascular morbidity and mortality is thought to be related to the 
epidemiologic increase in obesity.2, 16, 17 Signifi cant proportions of western populations now 






cardiovascular disease and type 2 diabetes mellitus (DM2).21, 22 Viscerally obese subjects in 
particular, are considered to have metabolic abnormalities that contribute to the increased 
risk of future cardiovascular events.23-25 The amount of visceral adipose tissue correlates with 
metabolic cardiovascular risk factors.26-29 Visceral obesity, quantifi ed by waist circumference, 
has been identifi ed as an independent risk factor for insulin resistance, cardiovascular disease, 
hypertension and stroke.30-33  In large epidemiological studies, waist circumference was shown 
to be a predictor of future cardiovascular events and cardiovascular mortality.17, 34 Based on 
these observations, visceral obesity has been applied as a tool for the identifi cation of subjects 
at risk of developing cardiovascular disease.35, 36    
Over the past decade, the prominent role of infl ammation has received increasing attention in 
the pathogenesis of atherosclerotic cardiovascular disease.37, 38 The infi ltration and accumu-
lation of lipoproteins in the arterial lamina intima initiates a local infl ammatory response4, 39 
resulting in the activation of endothelial cells.39 This activation of endothelial cells, through the 
expression of adhesion molecules, facilitates the transmigration of blood-derived infl amma-
tory cells, particularly monocytes, across the endothelial monolayer into the intima.40-43 Once in 
the intima, monocytes proliferate and diff erentiate into macrophages and take up lipoproteins, 
forming foam cells.44 In time, foam cell necrosis increases the lipid core of the atherosclerotic 
plaque. In some plaques, the local immune response results in the accumulation of smooth 
muscle cells which migrate from the medial layer.38 In parallel with these observations, the 
important role of infl ammation has also been observed in clinical studies. Elevated C-reactive 
protein (CRP) levels have been demonstrated in individuals with manifest cardiovascular dis-
ease and in subjects at risk for developing cardiovascular disease.38 CRP is known to associated 
with cardiovascular risk factors45 and atherosclerotic disease burden.46-48 Furthermore, CRP can 
predict future cardiovascular events.49 Elevated CRP levels are now used frequently as a marker 
of systemic infl ammation. Evidence has been provided demonstrating a strong association 
between infl ammation and plaque instability.50 The better understanding of the pathogenesis 
of atherosclerosis has resulted in viewing the process as a “response to injury” with lipoproteins 
or other risk factors as the injurious agents.44, 51 
IMAGING OF ATHEROSCLEROSIS
The increasing world wide mortality of atherosclerotic cardiovascular disease is thought to 
be related to the widespread under-recognition and under-treatment of individuals at risk 
of developing cardiovascular disease.52 Traditionally, evaluation of atherosclerosis was only 
possible at advanced clinical stages of the disease by either revealing arterial luminal narrow-
ing, or by assessing the eff ect of arterial stenosis on organ perfusion. Advances in imaging 
techniques have resulted in the development of new imaging modalities for the assessment of 
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atherosclerosis in earlier stages of the disease, which allow accurate evaluation of the arterial 
vascular structure and the possible changes in time. These imaging parameters do not only 
refl ect present disease burden, but can also be used to predict future events.53-57 Carotid intima 
media thickness (IMT) measured by ultrasound and vessel wall characteristics assessed by 
magnetic resonance imaging (MRI) are parameters of special interest in the primary prevention 
setting due to their non-invasive nature and the absence of radiation exposure. IMT is an estab-
lished measure of atherosclerotic disease burden which has been widely used and extensively 
validated both with cardiovascular risk factors, coronary atherosclerosis and outcome data.54-
64 MRI, on the other hand, is a relatively new imaging modality, which has been used in the 
assessment of atherosclerosis.65-67   Promising results have been demonstrated regarding the 
accuracy and reproducibility of the technique at the fi eld strength of 1.5 tesla.66, 68-72 Extending 
the MR vascular imaging to higher fi eld strength of 3 Tesla could further improve the accuracy 
of the technique in detecting diff erences in atherosclerotic disease burden. In addition, vascu-
lar MRI has not yet been validated extensively, because of its relative recent introduction. A fi rst 
step in this regard could be the evaluation of magnetic resonance carotid artery imaging with 
intima media thickness measurements using ultrasonography. 
TREATMENT OF EARLY ATHEROSCLEROSIS
The treatment strategy to prevent the progression of atherosclerosis has been focused on 
infl uencing the known risk factors for the development of cardiovascular disease. Changes in 
life style, by restricting caloric intake and increasing physical activity, are eff ective in improv-
ing cardiovascular risk factors and decreasing events.73  Lifestyle intervention is frequently 
complemented by drug therapy. In general, the focus of drug therapy has been to improve 
traditional risk factors such as LDL-cholesterol levels and blood pressure. In particular, statin 
treatment lowers levels of atherogenic lipoproteins, aff ects the progression of atherosclerosis 
and decreases clinical events and mortality from atherosclerotic cardiovascular disease.74-76 
Nevertheless, heart disease and stroke have remained the most common causes of death in 
the developed countries. New treatment approaches aff ecting the atherosclerotic mechanism 
may prove eff ective in retarding the atherosclerotic process, especially when combined with 
intensive life style treatment. With respect to insuline resistance, thiazolidinediones could 
be of interest. Thiazolidinediones, such as rosiglitazone, target the peroxisome-proliferator-
activated receptor γ (PPARγ).77 PPARγ is a nuclear transcription factor that modulates metabolic 
and infl ammatory gene repertoires. The complex biologic eff ects of rosiglitazone result from 
transactivation of metabolic and transrepression of infl ammatory target genes.78 Rosiglitazone 
improves insulin resistance, alters fat distribution from visceral to subcutaneous fat stores, and 
increases plasma HDL-c levels.79, 80 Clinically, rosiglitazone has been shown to improve insulin 






characteristics including its anti-infl ammatory eff ects suggest a possible anti-atherosclerotic 
potential for rosiglitazone. The eff ect of rosiglitazone on atherosclerosis has been studied 
using IMT. In DM2 patients, a benefi cial eff ect was observed on the progression of IMT after 
rosiglitazone treatment.82, 83 The eff ect of rosiglitazone in addition to lifestyle treatment on 
the progression of atherosclerosis has not yet been studied in viscerally obese subjects with 
systemic infl ammation but without diabetes and overt cardiovascular disease. The infl uence of 
rosiglitazone on infl ammation, adipose tissue distribution, insulin resistance and atherosclero-
sis as measured by 3 Tesla magnetic resonance vessel wall imaging are described in this thesis.
AIMS AND OUTLINE OF THE THESIS
The aim of this thesis was to explore the relation between visceral obesity and the accom-
panying metabolic disturbances, systemic infl ammation and the atherosclerotic process. A 
newly developed magnetic resonance vessel wall imaging technique was implemented in 
phenotyping patients and as a therapeutic endpoint in a randomised controlled setting. For 
this purpose, we pursued a three step approach. First, the magnetic resonance black blood 
vessel wall imaging technique at the magnetic fi eld strength of 3 Tesla was developed and 
validated. Secondly, the technique was used in the phenotyping of viscerally obese subjects 
with special focus on the role of systemic infl ammation. Finally, the impact of reducing visceral 
obesity and systemic infl ammation on the progression of atherosclerosis was assessed using 
lifestyle therapy and rosiglitazone or placebo treatment in a randomised controlled clinical trial 
that was named “A 52 week double-blind randomized controlled trial comparing the eff ect of 
Rosiglitazone versUs placeBo on the prevENtion of progression of atheroSclerosis in high risk 
patients without diabetes (RUBENS) trial”  
Part I: 3T magnetic resonance black blood vessel wall imaging 
Carotid magnetic resonance black blood vessel wall imaging at the magnetic fi eld strength of 3 
Tesla was developed for the assessment of atherosclerotic disease burden and possible changes 
in time. After development and optimisation, this technique was validated and its accuracy in 
measuring vascular structural characteristics was evaluated. The scanning procedure and the 
reproducibility of the MRI measurements are described in Chapter 2. The carotid MRI measure-
ments were further assessed with regard to the relation with cardiovascular risk factors and 
ultrasound measured IMT, a well validated intermediate endpoint in assessing atherosclerotic 
disease burden, in Chapter 3. 
Part II: Phenotyping of visceral obesity
After establishing the 3T vascular MRI, this technique was applied in the phenotyping of vis-
cerally obese subjects. In Chapter 4 MRI was used in vascular phenotyping of patients with 
Introduction 13
varying cardiovascular risk profi les. Vessel wall characteristics of visceral obese subjects with 
and without the Metabolic Syndrome were evaluated in comparison to patients who recently 
suff ered from a ST-segment elevation myocardial infarction. In chapter 5, the relation between 
elevated CRP levels and carotid atherosclerotic disease burden was assessed in subjects with 
visceral obesity. An association between visceral obesity, metabolic disturbances and systemic 
infl ammation has long been established. To further explore the interrelation between these 
variables, we studied the concentrations of apolipoprotein CI (ApoCI) in relation with systemic 
infl ammation and carotid atherosclerosis in viscerally obese subjects. ApoCI infl uences many 
proteins involved in the remodelling of lipoproteins in plasma and has been shown to posses 
modulating eff ects on the systemic infl ammatory response. Chapter 6 describes the infl uence 
of ApoCI concentrations in the presence of systemic infl ammation on carotid atherosclerotic 
disease burden. 
Part III: Visceral obesity and systemic infl ammation as therapeutic targets in atherosclerosis
In these chapters, we evaluated the impact of the manipulation of visceral obesity and systemic 
infl ammation on the progression of atherosclerosis in the setting of a randomised clinical trial. 
Chapter 7 describes the results of a randomised controlled intervention study evaluating the 
eff ect of rosiglitazone treatment in addition to intensive lifestyle therapy on the progression 
of carotid atherosclerosis in viscerally obese non-diabetic subjects with elevated CRP levels. 
Another endpoint of the study was the evaluation of the infl uence of rosiglitazone treatment 
in addition to lifestyle intervention on circulating endothelial progenitor cells and haematopoi-







 1. Fuster V, Voute J. MDGs: chronic diseases are not on the agenda. Lancet 2005 October 
29;366(9496):1512-4.
 2. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden 
of Disease Study. Lancet 1997 May 17;349(9063):1436-42.
 3. Stary HC, Chandler AB, Glagov S et al. A defi nition of initial, fatty streak, and intermediate lesions of 
atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, 
American Heart Association. Circulation 1994 May;89(5):2462-78.
 4. Skalen K, Gustafsson M, Rydberg EK et al. Subendothelial retention of atherogenic lipoproteins in 
early atherosclerosis. Nature 2002 June 13;417(6890):750-4.
 5. Napoli C, D’Armiento FP, Mancini FP et al. Fatty streak formation occurs in human fetal aortas and is 
greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein 
and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest 1997 
December 1;100(11):2680-90.
 6. Stary HC, Chandler AB, Dinsmore RE et al. A defi nition of advanced types of atherosclerotic lesions and 
a histological classifi cation of atherosclerosis. A report from the Committee on Vascular Lesions of the 
Council on Arteriosclerosis, American Heart Association. Circulation 1995 September 1;92(5):1355-74.
 7. Hackett D, Davies G, Maseri A. Pre-existing coronary stenoses in patients with fi rst myocardial infarc-
tion are not necessarily severe. Eur Heart J 1988 December;9(12):1317-23.
 8. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White 
Lecture 1995. Circulation 1996 October 15;94(8):2013-20.
 9. Faggiotto A, Ross R, Harker L. Studies of hypercholesterolemia in the nonhuman primate. I. Changes 
that lead to fatty streak formation. Arteriosclerosis 1984 July;4(4):323-40.
 10. de Boer OJ, van der Wal AC, Teeling P, Becker AE. Leucocyte recruitment in rupture prone regions of 
lipid-rich plaques: a prominent role for neovascularization? Cardiovasc Res 1999 February;41(2):443-9.
 11. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995 August 1;92(3):657-71.
 12. Nathan L, Chaudhuri G. Estrogens and atherosclerosis. Annu Rev Pharmacol Toxicol 1997;37:477-515.
 13. Assmann G, Cullen P, Jossa F, Lewis B, Mancini M. Coronary heart disease: reducing the risk: the 
scientifi c background to primary and secondary prevention of coronary heart disease. A worldwide 
view. International Task force for the Prevention of Coronary Heart disease. Arterioscler Thromb Vasc 
Biol 1999 August;19(8):1819-24.
 14. Gordon DJ, Rifkind BM. High-density lipoprotein--the clinical implications of recent studies. N Engl J 
Med 1989 November 9;321(19):1311-6.
 15. Luft FC. Molecular genetics of human hypertension. J Hypertens 1998 December;16(12 Pt 2):1871-8.
 16. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW, Jr. Body-mass index and mortality in a prospec-
tive cohort of U.S. adults. N Engl J Med 1999 October 7;341(15):1097-105.
 17. Yusuf S, Hawken S, Ounpuu S et al. Obesity and the risk of myocardial infarction in 27,000 participants 
from 52 countries: a case-control study. Lancet 2005 November 5;366(9497):1640-9.
 18. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity 
and diabetes in the United States. JAMA 2001 September 12;286(10):1195-200.
 19. Mokdad AH, Ford ES, Bowman BA et al. Diabetes trends in the U.S.: 1990-1998. Diabetes Care 2000 
September;23(9):1278-83.
 20. Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. The spread of the obesity 
epidemic in the United States, 1991-1998. JAMA 1999 October 27;282(16):1519-22.
 21. Adams KF, Schatzkin A, Harris TB et al. Overweight, obesity, and mortality in a large prospective 
cohort of persons 50 to 71 years old. N Engl J Med 2006 August 24;355(8):763-78.
 22. Jee SH, Sull JW, Park J et al. Body-mass index and mortality in Korean men and women. N Engl J Med 
2006 August 24;355(8):779-87.
Introduction 15
 23. Despres JP, Lemieux I, Prud’homme D. Treatment of obesity: need to focus on high risk abdominally 
obese patients. BMJ 2001 March 24;322(7288):716-20.
 24. Van Gaal LF, Vansant GA, De L, I. Upper body adiposity and the risk for atherosclerosis. J Am Coll Nutr 
1989 December;8(6):504-14.
 25. Wong S, Janssen I, Ross R. Abdominal adipose tissue distribution and metabolic risk. Sports Med 
2003;33(10):709-26.
 26. Pascot A, Lemieux I, Prud’homme D et al. Reduced HDL particle size as an additional feature of the 
atherogenic dyslipidemia of abdominal obesity. J Lipid Res 2001 December;42(12):2007-14.
 27. Pouliot MC, Despres JP, Nadeau A et al. Visceral obesity in men. Associations with glucose tolerance, 
plasma insulin, and lipoprotein levels. Diabetes 1992 July;41(7):826-34.
 28. Lemieux I, Pascot A, Prud’homme D et al. Elevated C-reactive protein: another component of the 
atherothrombotic profi le of abdominal obesity. Arterioscler Thromb Vasc Biol 2001 June;21(6):961-7.
 29. Tchernof A, Lamarche B, Prud’homme D et al. The dense LDL phenotype. Association with plasma 
lipoprotein levels, visceral obesity, and hyperinsulinemia in men. Diabetes Care 1996 June;19(6):629-
37.
 30. Banerji MA, Lebowitz J, Chaiken RL, Gordon D, Kral JG, Lebovitz HE. Relationship of visceral adipose 
tissue and glucose disposal is independent of sex in black NIDDM subjects. Am J Physiol 1997 
August;273(2 Pt 1):E425-E432.
 31. Pouliot MC, Despres JP, Lemieux S et al. Waist circumference and abdominal sagittal diameter: best 
simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related 
cardiovascular risk in men and women. Am J Cardiol 1994 March 1;73(7):460-8.
 32. Kuo CS, Hwu CM, Chiang SC et al. Waist circumference predicts insulin resistance in off spring of 
diabetic patients. Diabetes Nutr Metab 2002 April;15(2):101-8.
 33. Poirier P, Lemieux I, Mauriege P et al. Impact of waist circumference on the relationship between 
blood pressure and insulin: the Quebec Health Survey. Hypertension 2005 March;45(3):363-7.
 34. Pischon T, Boeing H, Hoff mann K et al. General and abdominal adiposity and risk of death in Europe. 
N Engl J Med 2008 November 13;359(20):2105-20.
 35. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide defi nition. A Consensus State-
ment from the International Diabetes Federation. Diabet Med 2006 May;23(5):469-80.
 36. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an 
American Heart Association/National Heart, Lung, and Blood Institute Scientifi c Statement. Circula-
tion 2005 October 25;112(17):2735-52.
 37. Libby P, Ridker PM, Maseri A. Infl ammation and atherosclerosis. Circulation 2002 March 5;105(9):1135-
43.
 38. Libby P. Infl ammation in atherosclerosis. Nature 2002 December 19;420(6917):868-74.
 39. Leitinger N. Oxidized phospholipids as modulators of infl ammation in atherosclerosis. Curr Opin 
Lipidol 2003 October;14(5):421-30.
 40. POOLE JC, FLOREY HW. Changes in the endothelium of the aorta and the behaviour of macrophages 
in experimental atheroma of rabbits. J Pathol Bacteriol 1958 April;75(2):245-51.
 41. Eriksson EE, Xie X, Werr J, Thoren P, Lindbom L. Importance of primary capture and L-selectin-depen-
dent secondary capture in leukocyte accumulation in infl ammation and atherosclerosis in vivo. J Exp 
Med 2001 July 16;194(2):205-18.
 42. Cybulsky MI, Gimbrone MA, Jr. Endothelial expression of a mononuclear leukocyte adhesion mol-
ecule during atherogenesis. Science 1991 February 15;251(4995):788-91.
 43. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice defi -
cient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci U S 






 44. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993 April 
29;362(6423):801-9.
 45. Festa A, D’Agostino R, Jr., Howard G, Mykkanen L, Tracy RP, Haff ner SM. Chronic subclinical infl amma-
tion as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). 
Circulation 2000 July 4;102(1):42-7.
 46. Hak AE, Stehouwer CD, Bots ML et al. Associations of C-reactive protein with measures of obesity, 
insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb 
Vasc Biol 1999 August;19(8):1986-91.
 47. Jarvisalo MJ, Harmoinen A, Hakanen M et al. Elevated serum C-reactive protein levels and early arte-
rial changes in healthy children. Arterioscler Thromb Vasc Biol 2002 August 1;22(8):1323-8.
 48. Blackburn R, Giral P, Bruckert E et al. Elevated C-reactive protein constitutes an independent predictor 
of advanced carotid plaques in dyslipidemic subjects. Arterioscler Thromb Vasc Biol 2001 Decem-
ber;21(12):1962-8.
 49. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and preven-
tion. Circulation 2003 January 28;107(3):363-9.
 50. Redgrave JN, Lovett JK, Gallagher PJ, Rothwell PM. Histological assessment of 526 symptomatic 
carotid plaques in relation to the nature and timing of ischemic symptoms: the Oxford plaque study. 
Circulation 2006 May 16;113(19):2320-8.
 51. Libby P. Changing concepts of atherogenesis. J Intern Med 2000 March;247(3):349-58.
 52. Bhatt DL, Steg PG, Ohman EM et al. International prevalence, recognition, and treatment of cardiovas-
cular risk factors in outpatients with atherothrombosis. JAMA 2006 January 11;295(2):180-9.
 53. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with 
carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007 January 
30;115(4):459-67.
 54. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness 
and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997 September 
2;96(5):1432-7.
 55. Johnsen SH, Mathiesen EB, Joakimsen O et al. Carotid atherosclerosis is a stronger predictor of myo-
cardial infarction in women than in men: a 6-year follow-up study of 6226 persons: the Tromso Study. 
Stroke 2007 November;38(11):2873-80.
 56. Murakami S, Otsuka K, Hotta N et al. Common carotid intima-media thickness is predictive of all-cause 
and cardiovascular mortality in elderly community-dwelling people: Longitudinal Investigation for 
the Longevity and Aging in Hokkaido County (LILAC) study. Biomed Pharmacother 2005 October;59 
Suppl 1:S49-S53.
 57. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK, Jr. Carotid-artery intima and 
media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular 
Health Study Collaborative Research Group. N Engl J Med 1999 January 7;340(1):14-22.
 58. Baldassarre D, Amato M, Bondioli A, Sirtori CR, Tremoli E. Carotid artery intima-media thickness mea-
sured by ultrasonography in normal clinical practice correlates well with atherosclerosis risk factors. 
Stroke 2000 October;31(10):2426-30.
 59. Chambless LE, Heiss G, Folsom AR et al. Association of coronary heart disease incidence with carotid 
arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 
1987-1993. Am J Epidemiol 1997 September 15;146(6):483-94.
 60. Ebrahim S, Papacosta O, Whincup P et al. Carotid plaque, intima media thickness, cardiovascular risk 
factors, and prevalent cardiovascular disease in men and women: the British Regional Heart Study. 
Stroke 1999 April;30(4):841-50.
 61. Lekakis JP, Papamichael CM, Cimponeriu AT et al. Atherosclerotic changes of extracoronary arteries 
are associated with the extent of coronary atherosclerosis. Am J Cardiol 2000 April 15;85(8):949-52.
 62. Mack WJ, LaBree L, Liu C, Selzer RH, Hodis HN. Correlations between measures of atherosclerosis change 
using carotid ultrasonography and coronary angiography. Atherosclerosis 2000 June;150(2):371-9.
Introduction 17
 63. Vasankari T, Ahotupa M, Toikka J et al. Oxidized LDL and thickness of carotid intima-media are asso-
ciated with coronary atherosclerosis in middle-aged men: lower levels of oxidized LDL with statin 
therapy. Atherosclerosis 2001 April;155(2):403-12.
 64. Amato M, Montorsi P, Ravani A et al. Carotid intima-media thickness by B-mode ultrasound as sur-
rogate of coronary atherosclerosis: correlation with quantitative coronary angiography and coronary 
intravascular ultrasound fi ndings. Eur Heart J 2007 September;28(17):2094-101.
 65. Adams GJ, Greene J, Vick GW, III et al. Tracking regression and progression of atherosclerosis in human 
carotid arteries using high-resolution magnetic resonance imaging. Magn Reson Imaging 2004 
November;22(9):1249-58.
 66. Shinnar M, Fallon JT, Wehrli S et al. The diagnostic accuracy of ex vivo MRI for human atherosclerotic 
plaque characterization. Arterioscler Thromb Vasc Biol 1999 November;19(11):2756-61.
 67. Yuan C, Beach KW, Smith LH, Jr., Hatsukami TS. Measurement of atherosclerotic carotid plaque size in 
vivo using high resolution magnetic resonance imaging. Circulation 1998 December 15;98(24):2666-
71.
 68. Corti R, Fayad ZA, Fuster V et al. Eff ects of lipid-lowering by simvastatin on human atherosclerotic 
lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circula-
tion 2001 July 17;104(3):249-52.
 69. Kang X, Polissar NL, Han C, Lin E, Yuan C. Analysis of the measurement precision of arterial lumen and 
wall areas using high-resolution MRI. Magn Reson Med 2000 December;44(6):968-72.
 70. Chan SK, Jaff er FA, Botnar RM et al. Scan reproducibility of magnetic resonance imaging assessment 
of aortic atherosclerosis burden. J Cardiovasc Magn Reson 2001;3(4):331-8.
 71. Varghese A, Crowe LA, Mohiaddin RH et al. Inter-study reproducibility of 3D volume selective fast spin 
echo sequence for quantifying carotid artery wall volume in asymptomatic subjects. Atherosclerosis 
2005 December;183(2):361-6.
 72. Varghese A, Crowe LA, Mohiaddin RH et al. Interstudy reproducibility of three-dimensional volume-
selective fast spin echo magnetic resonance for quantifying carotid artery wall volume. J Magn Reson 
Imaging 2005 February;21(2):187-91.
 73. Chiuve SE, McCullough ML, Sacks FM, Rimm EB. Healthy lifestyle factors in the primary prevention 
of coronary heart disease among men: benefi ts among users and nonusers of lipid-lowering and 
antihypertensive medications. Circulation 2006 July 11;114(2):160-7.
 74. de GE, Jukema JW, Montauban van Swijndregt AD et al. B-mode ultrasound assessment of pravastatin 
treatment eff ect on carotid and femoral artery walls and its correlations with coronary arteriographic 
fi ndings: a report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll Cardiol 1998 
June;31(7):1561-7.
 75. Hodis HN, Mack WJ, LaBree L et al. Reduction in carotid arterial wall thickness using lovastatin and 
dietary therapy: a randomized controlled clinical trial. Ann Intern Med 1996 March 15;124(6):548-56.
 76. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandina-
vian Simvastatin Survival Study (4S). Lancet 1994 November 19;344(8934):1383-9.
 77. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thia-
zolidinedione is a high affi  nity ligand for peroxisome proliferator-activated receptor gamma (PPAR 
gamma). J Biol Chem 1995 June 2;270(22):12953-6.
 78. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004 September 9;351(11):1106-18.
 79. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is eff ective 
in patients with type 2 diabetes. J Clin Endocrinol Metab 2001 January;86(1):280-8.
 80. Viljanen AP, Virtanen KA, Jarvisalo MJ et al. Rosiglitazone treatment increases subcutaneous adipose 
tissue glucose uptake in parallel with perfusion in patients with type 2 diabetes: a double-blind, 
randomized study with metformin. J Clin Endocrinol Metab 2005 December;90(12):6523-8.
 81. Mohanty P, Aljada A, Ghanim H et al. Evidence for a potent antiinfl ammatory eff ect of rosiglitazone. J 






 82. Hedblad B, Zambanini A, Nilsson P, Janzon L, Berglund G. Rosiglitazone and carotid IMT progression 
rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main 
results from the Rosiglitazone Atherosclerosis Study. J Intern Med 2007 March;261(3):293-305.
 83. Stocker DJ, Taylor AJ, Langley RW, Jezior MR, Vigersky RA. A randomized trial of the eff ects of rosi-
glitazone and metformin on infl ammation and subclinical atherosclerosis in patients with type 2 
diabetes. Am Heart J 2007 March;153(3):445-6.
PAR T I




Assessment of the Carotid Artery 
at 3T MR Imaging: a Study on 
Reproducibility
Reza Alizadeh Dehnavi MD1, Joost Doornbos PhD2, Jouke T. 
Tamsma MD1, Matthias Stuber PhD3, Hein Putter PhD4, Rob J. 
van der Geest MS5, Hildo J. Lamb MD2, Albert de Roos MD2
1Vascular Medicine, Department of General Internal Medicine 
and Endocrinology, Leiden University Medical Center, Leiden, The 
Netherlands
2Department of Radiology, Leiden University Medical Center, Leiden, 
The Netherlands
3Department of Radiology, Division of MRI Research, Johns Hopkins 
University Medical School, Baltimore, Maryland, USA
4Department of Medical Statistics and Bio-Informatics, Leiden 
University Medical Center, Leiden, The Netherlands
5Image Processing, Department of Radiology, Leiden University Medical 
Center, Leiden, The Netherlands








To examine the reproducibility of carotid artery dimension measurements using 3T MRI.
Materials and Methods
Ten healthy volunteers underwent three scans on two occasions for assessment of total vessel 
wall area (TVWA), total luminal area (TLA), and minimum (MinT) and maximum (MaxT) vessel 
wall thickness. A double inversion-recovery (IR) fast gradient-echo (FGRE) sequence was used 
on a commercial 3T system. During the fi rst visit the subjects were scanned twice. The third scan 
was performed at least four days later. One observer traced all scans, and a second observer 
retraced the fi rst scan series.
Results
For TVWA an interclass correlation (ICC) of 0.994 was calculated with all three scans taken into 
account. The interobserver ICC was 0.984. The agreement between the scans for TLA showed 
an ICC of 0.982 with an interobserver ICC of 0.998. For MinT and MaxT an ICC of 0.843 and 0.935 
were calculated, with interobserver ICCs of 0.860 and 0.726, respectively.
Conclusion
With the use of a commercial 3T MR system, TVWA, TLA, and wall thickness measurements of 
the carotid artery can be assessed with good reproducibility.
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INTRODUCTION
Cardiovascular disease is the leading cause of morbidity and mortality in the western world, 
and atherosclerosis is the primary underlying pathophysiological process. Atherosclerosis 
is regarded as a chronic infl ammatory disease that can start at an early age1 and progress 
throughout life, causing structural changes in the arterial wall.2 This process is modulated by 
known risk factors such as dyslipidemia, diabetes, and hypertension, and can result in more 
prominent arterial wall structural changes in subjects who are at risk for developing cardio-
vascular disease.3 The relevance of arterial vascular structural changes for both clinical and 
research settings has been demonstrated in several studies.4-9
The carotid intima media thickness (IMT) as measured by high-resolution B-mode ultrasound 
imaging has been shown to correlate both with clinical cardiovascular disease and the level of 
risk factors present.5-8 Both the absolute IMT and its increase have been demonstrated to be 
predictive of future coronary events in subjects with prior coronary heart disease.9 The predic-
tive power of the IMT has been shown to be independent of other risk factors.4-9 Furthermore, 
the importance of tomographic assessments of the arterial wall has been illustrated in stud-
ies in which, after a pharmacological intervention, a reduction in either the event rate or the 
vessel wall area was observed disproportionately to or in the absence of luminal changes.10-12 
Accurate assessments of the arterial vascular structure and possible changes in that structure 
over time are therefore of great importance because they both refl ect the current disease 
burden and are predictive of future events. Magnetic resonance imaging (MRI) has emerged 
in recent years as a promising noninvasive imaging modality for the serial assessment of 
atherosclerosis.13-15 Its ability to quantify total plaque volume and disease burden has been 
demonstrated.16-18 The accuracy of the technique for assessing the atherosclerotic plaques was 
validated in comparison with histopathology in an ex vivo study.19 MRI has also been shown to 
be able to characterize plaque composition in vivo.20
The introduction of whole-body 3.0T fi eld-strength magnets has created new opportunities to 
further develop MRI. Improved signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), and 
image quality of the carotid artery images at 3T in comparison to 1.5T fi eld strength have been 
demonstrated.21 However, to our knowledge, no reproducibility studies have been conducted 
to date. Accordingly, the aim of the present study was to test the reproducibility of the carotid 







Ten healthy adult subjects (seven males and three females, 25-79 years old, mean age = 57 
years) underwent three MRI scans on two diff erent occasions. During the fi rst visit and after 
the fi rst scan (SC1), the subjects were removed from the scanner, the coils were removed, and 
the subjects were repositioned. After this procedure a second scan (SC2) was performed. The 
third scan (SC3) was performed at least four days after the fi rst visit. The local medical ethics 
committee approved the study, and all volunteers gave informed consent.
MRI
MRI was performed using a 3T scanner (Achieva; Philips, Best, The Netherlands) using a standard 
phased-array coil with two fl exible elements of 14 × 17 cm. The subjects were scanned in the supine 
position with the neck positioned at the isocenter of the magnet. A special cushion was used to fi x 
the position of the neck and head to reproduce a stable fl exion angle. We avoided left-right rota-
tion by positioning the patient’s nose in the midsagittal plane. Figure 1 demonstrates the scanning 
setup. In all subjects the left carotid artery was examined. Three survey scans were performed: the 
fi rst used a fast gradient-echo (FGRE) sequence and resulted in 20 contiguous transverse slices 
(acquired pixel size = 1 mm × 1.23 mm × 5.0 mm, fi eld of view (FOV) = 300 mm, echo time (TE) = 
Figure 1. The scanning setup.
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3.8 msec, repetition time (TR) = 7.7 msec, and fl ip angle = 20°). We planned the second scout view 
by defi ning three points (three-point planscan tool) in the center of the common, internal, and 
external carotid arteries, which resulted in an oblique sagittal view of the carotid bifurcation (Fig. 
2). The third survey was planned in an oblique sagittal plane, following the course of the common 
carotid artery, to obtain an oblique coronal plane (Fig. 2). For the second and third surveys, an FGRE 
sequence was used with dual inversion recovery (IR) and ECG triggering (FOV = 140 mm, matrix 
= 304 × 304 pixels reconstructed to 512 × 512 pixels. Acquired slice thickness = 2.5 mm, thickness 
of the reinverted slice = 3 mm, fl ip angle = 20°, TR = 11.8 msec, and TE = 3.6 msec). A standardized 
series of oblique axial slices were planned on the sagittal and coronal planes, perpendicular to the 
course of the common carotid artery in both views (Fig. 2). A total of eight contiguous transverse 
slices with 2-mm thickness were then acquired for the analysis starting from the fl ow divider in the 
proximal (caudal) direction covering 1.6 cm of the carotid bulb and the common carotid artery 
(Fig. 3). The fl ow divider on the oblique sagittal scouts was used as a landmark to ensure that the 
acquisition was planned at the same location for all three scans. A dual IR (black-blood), spoiled 
segmented k-space FGRE sequence with spectral selective fat suppression was used to maximize 
contrast between the carotid wall and the lumen blood pool. Images were acquired at each RR 
interval (TE = 3.6 msec, TR = 12 msec, fl ip angle = 45°, and two signal averages). ECG triggering 
was used for data acquisition at the end-diastole. A reinversion slice thickness of 3 mm was used. 
The FOV was 140 mm. With a matrix size of 306, a voxel size of 0.46 mm × 0.46 mm × 2 mm was 
obtained. Each MR study took approximately 30 minutes depending on the cardiac frequency.
A GRE technique may be more prone to residual blood-pool signal than fast spin-echo (FSE) 
imaging. We performed an optimization procedure to avoid this possibility by optimally null-
ing the signal from blood utilizing a heart-rate-dependent inversion time (TI) according to the 
Figure 2. Oblique sagittal view of the carotid bifurcation, and oblique coronal plane of the common 
carotid artery. The yellow lines indicate beginning, end and the middle of the stack. Red lines indicate 
the middle of slices. Note that the slices are planned perpendicular to the course of the common carotid 






formula proposed by Fleckenstein et al.22 Furthermore, to maximize the likelihood for fl ow 
exchange (and therefore signal attenuation in the blood pool) in the imaged slice, the slice 
thickness of the reinverted slice was only 1 mm thicker than that of the imaged slice. During the 
developmental phase of the protocol, the radiofrequency (RF) excitation angle, the number of 
k-space segments, and the trigger delay were carefully optimized for image quality. During that 
process we tried to maximize the conspicuity of the inner and outer borders of the vessel wall.
Image analysis
We analyzed all of the images using the VesselMASS software package developed at our institu-
tion.23 This software package allows the semiautomated detection of the luminal and outer wall 
boundaries of the vessel wall from MR images, and the subsequent derivation of various quan-
titative parameters describing the vessel wall. All three scan series were traced by one observer. 
The fi rst scan series was also traced by a second observer. The observers were blinded to each 
other’s results. We calculated the vessel wall area by subtracting the luminal area from the outer 
contour area. We calculated the total vessel wall area (TVWA) by adding the vessel wall area from 
all eight slices, and the total luminal area (TLA) by adding the luminal area in all eight slices. We 
also calculated a vascular wall area-luminal area (W/L) index by dividing the TVWA by the TLA. 
Minimum vessel wall thickness (MinT) and maximum vessel wall thickness (MaxT) measurements 
were obtained from the slice at a distance of 1.8 cm from the fl ow divider in each scan series. We 
automatically divided the contour of the vessel wall on this slice into six, 10, 20, and 100 segments 
Figure 3. Transverse slices acquired starting from the fl ow-divider in the proximal (caudal) direction 
covering 1.6 cm of the carotid bulb and the common carotid artery.
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using the centerline method as previously described.24 An average thickness was automatically 
calculated per segment, and the MinT and MaxT values per segmentation group were used for 
the analysis. We evaluated these segmentation groups to determine the best analysis method for 
obtaining reproducible thickness measurements.
Statistical analysis
Interclass correlations (ICCs) were calculated to quantify the agreement between the measure-
ments obtained at various time points and analyzed by diff erent observers. Per endpoint, 
the ICC was calculated for the following measurements: SC1 vs. 2, SC1 vs. 3, and SC2 vs. 3, all 
three scans at the same time, and fi nally observer 1 vs. observer 2 (for SC1 only). Bland-Altman 
plots for the above pair wise comparisons were also made.25 For all endpoints of the study, 
both intra- and interobserver mean relative errors (MREs) were calculated. For this calculation, 
fi rst the absolute diff erence between the measurements was calculated per volunteer for the 
respective endpoint. The absolute diff erence was then divided by the average of the measure-
ments to yield the relative error. We then calculated the mean absolute diff erence (MAD) and 
the mean relative error (MRE) for all endpoints by averaging the absolute diff erence and rela-
tive error calculated for all individual volunteers, respectively. It should be noted that for the 
Figure 4. Scatter plot of the measurements of total vessel wall area (cm²). Note the large inter-volunteer 






intraobserver calculation of the absolute diff erence and the mean, all three analyses of the fi rst 
observer were used.
RESULTS
A total of four analyses per volunteer were available (Table 1). Figure 4 demonstrates a scatter 
plot of all TVWA measurements per volunteer. The agreement between the diff erent measure-
ments was calculated using the ICCs. An overview of the calculated ICCs for the TVWA, TLA, 
and W/L index is provided in Table 2. The calculated agreement between the measurements 
remained very similar per endpoint irrespectively of the measurement combination used. For 
TVWA an ICC of 0.994 was calculated when all three measurements were taken into account. 
The observers had an ICC of 0.984 for this endpoint. The Bland-Altman plots, including limits of 










































1 1.907 1.9164 1.8580 1.9522 2.9250 2.8175 2.7750 2.8835
2 2.0887 2.0834 2.0019 2.0579 2.6795 2.8450 2.7595 2.6025
3 3.1526 3.0523 3.0597 3.1108 5.5465 5.2595 5.0945 5.5765
4 2.5088 2.5408 2.4691 2.7321 4.1110 4.3755 4.2120 4.0085
5 2.0109 2.0345 2.1135 1.9997 4.3570 4.4125 4.3405 4.2105
6 1.0835 1.1082 1.0856 1.3138 3.3180 3.2005 2.9380 3.2815
7 1.7038 1.8402 1.9313 1.7919 2.6215 2.4760 2.8530 2.5620
8 2.1620 2.1883 2.1443 2.1749 3.5720 3.6295 3.3425 3.4940
9 3.0612 3.0798 3.0894 3.1954 5.5695 5.8275 5.7155 5.5300
10 1.4655 1.4150 1.4193 1.4950 4.0350 3.8610 3.8455 3.9580
TVWA: Total vessel wall area
TLA: Total luminal area
SC 1;2;3: Scan 1;2;3
Table 2. Interclass correlations between the diff erent scan series for TVWA, TLA and W/L index.
Scan 1 vs 2 Scan 1 vs 3 Scan 2 vs 3 All three scans Inter-observer
TVWA 0.996 0.990 0.996 0.994 0.984
TLA 0.986 0.975 0.984 0.982 0.998
W/L index 0.965 0.973 0.978 0.971 0.960
TVWA: Total vessel wall area
TLA: Total luminal area
W/L index: Vascular wall area/luminal area index 






A: Bland-Altman plot for Total Vessel Wall Area (cm²), SC1 versus SC3.
B: Bland-Altman plot for TLA (cm²), SC1 versus SC3. 
C: Bland-Altman plot for vessel wall area/luminal area index, SC1 versus SC3.
D:  Bland-Altman plot for Minimum vessel wall thickness, SC1 versus SC3.






agreement for SC1 vs. SC3, are shown in Fig. 5 for TVWA, TLA, W/L index, MinT, and MaxT when 
six segments were used to assess the vascular thickness. No dependence of the diff erence vs. 
the mean was observed. When all three scans were considered, the agreement between the 
analyses for TLA resulted in an ICC of 0.982, with an interobserver ICC of 0.998. For the W/L 
index the ICC calculated was 0.971, with an interobserver ICC of 0.960. Dividing the slice into 
six segments resulted in optimal agreement between the measurements for both MinT and 
MaxT (see Table 3). When the analysis was performed based on all three scans, ICCs of 0.843 and 
0.935 were calculated for MinT and MaxT, respectively (six-segment method). The interobserver 
agreement for this segmentation method for MinT and MaxT resulted in ICC = 0.860 and 0.726, 
respectively. Furthermore, both intra- and interobserver MREs were calculated for all endpoints 
(see Table 4). The intraobserver MRE was calculated to be 2.6% for TVWA, and the interobserver 
MRE was 4.5%.
DISCUSSION
This study shows a high agreement between the repeated measurements of the TVWA, TLA, 
and W/L index of the carotid arteries as assessed using dual-inversion black-blood segmented 
k-space GRE imaging at 3T. Excellent image quality with high vessel wall-lumen contrast was 
obtained in all subjects, and a good reproducibility of the MinT and MaxT measurements at a 
predefi ned position in the common carotid artery relative to the fl ow divider was demonstrated.
The reliability of MRI measurements at 1.5T was previously demonstrated in a population with 
pre-existing atherosclerotic plaques.16 Errors in the vessel wall area of 2.6% and 3.5% were 
Table 3. Interclass correlations between the diff erent scan series minimum and maximum vessel wall 
thickness on the slice with 1.8 cm distance from the fl ow-divider.
Scan 1 vs 2 Scan 1 vs 3 Scan 2 vs 3 All three scans Inter-observer
Minimum vessel wall 
thickness 
6 Segments 0.873 0.923 0.740 0.843 0.860
10 Segments 0.699 0.920 0.694 0.781 0.807
20 Segments 0.632 0.910 0.697 0.761 0.840
100 Segments 0.602 0.881 0.654 0.732 0.809
Maximum vessel wall 
thickness
6 Segments 0.923 0.925 0.958 0.935 0.726
10 Segments 0.919 0.871 0.930 0.907 0.718
20 Segments 0.895 0.862 0.924 0.894 0.717
100 Segments 0.903 0.901 0.931 0.912 0.800




















































































































































































































































































































































































































































































































































































































































































































































































































































































































reported for the aortic and carotid plaques, respectively. Errors in wall volume measurements in 
hypercholesterolemic subjects were shown in another study (also performed at 1.5T) to range 
from 3% to 6%.17 The mean relative error of 2.6% obtained in the present study at 3T for vessel 
wall area measurements in healthy adult subjects with a wide age range further confi rms these 
previous observations. However, it is diffi  cult to determine whether the fi eld strength of 3T is 
superior to 1.5T, as far as the reproducibility of the vessel wall measurements is concerned, by 
comparing the above-mentioned results. The present data was obtained from a heterogeneous 
population without occlusive carotid plaques; however, most previous studies of reproducibility 
were performed in more homogeneous populations with pre-existing carotid atherosclerotic 
disease, which aff ects the statistical outcome in terms of reproducibility and relative error. Real 
evidence can only be obtained by scanning one group of volunteers at both fi eld strengths and 
comparing the data.
We observed a high level of agreement for TVWA between the diff erent analyses of the scans 
as evaluated by one observer (ICC = 0.994). The interobserver agreement for this endpoint 
was slightly lower (ICC = 0.984). The agreement between measurements for the MaxT (ICC = 
0.935), when using six segments, was lower than that of TVWA. A further decrease in agree-
ment was seen when six segments were used for the assessment of the MinT (ICC = 0.843). 
The precision of such measurements decreases when smaller structures are measured (i.e., the 
total quantity of wall area and wall thickness). Wall thickness measurements are obtained using 
100 centerlines. One can obtain these measurements of wall thickness from all 100 centerlines 
individually or by grouping the centerlines into a predefi ned number of segments, and then 
calculating the average per segment (e.g., 5 centerlines × 20 segments). Table 3 illustrates that 
the ICC for MinT decreases when the number of wall segments increases (thereby decreasing 
the number of centerlines per segment). A decrease in the number of centerlines per segment 
is expected to result in a relative lower calculated average MinT, which will in turn result in a 
decreased precision. On the other hand, this eff ect is not observed when all 100 centerlines 
are used individually to estimate the MaxT. The precision for MaxT measurements does not 
decrease when 100 centerlines are used individually, due to the relatively larger wall thickness. 
One would expect higher reproducibility of thickness measurements in patients with pre-
existing atherosclerotic plaques or elevated disease burden using this method. This eff ect on 
the precision of the total measured quantity may also contribute to the observed agreement 
between the diff erent analyses of TLA. Compared to TVWA, a lower ICC of 0.982 was calculated 
for the TLA measurements. The diff erences between the diff erent measurements were in this 
case less prominent due to the greater total quantity assessed. TLA ranged from 2.48 to 5.83 
cm2 (mean = 3.84 cm2), whereas TVWA ranged from 1.08 to 3.20 cm2 (mean = 2.13 cm2). The 
agreement between the measurements for the W/L index was very good (ICC = 0.971), although 
slightly lower than its components. This index could be important when the technique is used 
to assess the long-term eff ects of an intervention, since both of its components have been 
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shown to change after an intervention. Earlier reports have shown a reduction in either the 
event rate or the vessel wall area after a pharmacological intervention disproportionately to 
or in the absence of luminal changes.10-12 In a follow-up study of patients on statin therapy, no 
luminal changes were observed in the thoracic aorta by MRI after a short treatment period of 
six months, but plaque volume and area decreased signifi cantly.12 Prolonged treatment has 
been shown to signifi cantly increase the luminal area with a range of 4% to 6% in both the 
aorta and the carotid artery, along with a regression in the vessel wall thickness and area of 
up to 20%.11 The W/L index together with the TLA could also provide information about the 
early stages of the atherosclerotic process, during which outward remodeling can occur. This 
process is defi ned by an increase in the vessel wall disease burden (plaque) in the absence 
of luminal changes.26 Since the index contains the two components that could possibly be 
aff ected by the atherosclerotic process or an intervention, it has the potential to detect changes 
more sensitively.
Technical requirements for high-resolution carotid vessel imaging include high spatial 
resolution, high contrast between the vessel wall and blood pool without fl ow artifacts, high 
contrast between the vessel wall and surrounding fat, and suppression of motion artifacts. FSE 
sequences with multiple contrast weightings are commonly used to meet these requirements, 
and some reports have shown reliable results with GRE sequences.27 Recent studies have 
shown the reproducibility of a 3D volume-selective FSE sequence in both patients with known 
atherosclerotic disease28 and asymptomatic patients.29 While most prior work on carotid vessel 
wall imaging was performed at 1.5T using FSE techniques, the present study was conducted 
at 3T using a spoiled GRE (SPGRE) imaging sequence. During the developmental phase of 
our protocol, we initially focused on the use of dual-inversion FSE imaging as well. However, 
based on our prior experience with black-blood imaging of the coronary vessel wall at 1.5T 
and 3T30, 31, we decided to simultaneously work on the development of a dual-inversion SPGRE 
technique. We found that both the visual sharpness and contrast of the carotid vessel wall were 
superior on the SPGRE images as compared to those obtained with the more conventional 
FSE approach. Since our goal was to optimize black-blood carotid vessel wall image quality at 
3T, we decided to move forward with the SPGRE imaging technique. However, based on prior 
and extensive experience with FSE imaging at 1.5T, the use of FSE imaging at 3T may have to 
be revisited, and specifi c 3T issues, including the specifi c absorption rate (SAR), prolonged T1, 
and increased B1 inhomogeneity, may have to be addressed to further optimize FSE imaging 
of the carotids. Here, in one of the fi rst studies to assess the measurement capabilities of MRI in 
the carotid artery at 3T, we demonstrated the high reproducibility of vessel wall area measure-
ments using a dual-inversion segmented k-space GRE imaging technique.
Black-blood techniques are commonly used to achieve fl ow suppression, even though they 






pulse that inverts the longitudinal magnetization of the entire volume in the transmit coil. This 
is immediately followed by a slice-selective RF pulse that reinverts the longitudinal magnetiza-
tion at the anatomical level of interest. By placing the double IR prepulse before a period of 
rapid fl ow and acquiring data during the slow fl ow, one can maximize the fl ow suppression of 
intraluminal signal.33 In a study using the black-blood technique29, residual blood signal was 
observed in asymptomatic subjects. This is thought to be the result of recirculation in the bulb 
region, which can be infl uenced by several factors.34 Two such factors are the blood fl ow veloc-
ity (which is infl uenced by, e.g., the extent of possible stenoses) and the distensibility of the 
carotid artery (which can vary with age and the risk profi le). Our experience suggests that one 
can minimize fl ow artifacts caused by the residual blood signal by planning the transverse slices 
perpendicular to the fl ow direction. Motion artifacts can be reduced by cardiac triggering, and 
perivascular fat signal suppression can be achieved with the use of fat-saturation prepulses. The 
fi eld strength at which images are acquired is another factor that can infl uence the precision of 
the measurements. In a recent study35 a considerable increase in SNR was observed when the 
fi eld strength was increased from 1.5T to 3T. This increase could be traded for a better in-plane 
resolution, which in turn could improve the accuracy of the measurements. This is refl ected by 
the improved detection of complex atherosclerotic plaque at 3T, as validated by histology36, 
and the increased SNR, CNR, and improved image quality of the carotid images at 3T21 as 
compared to 1.5T. In the current study we evaluated a GRE sequence with 0.46 mm × 0.46 mm 
× 2 mm spatial resolution, which is comparable to that employed in recent studies at 1.5T.28, 29
We observed good reproducibility of the vessel wall thickness measurements at a fi xed posi-
tion in the carotid artery (see Table 3). Diff erent segmentation methods were used to evaluate 
the optimum method of analysis for the reproducible thickness measurements. Averages 
calculated per segment when the vessel contour was divided into six segments were most 
reproducible for MinT and MaxT. The interobserver agreement for MinT was also optimal using 
this segmentation method. For the MaxT, the highest agreement between the observers was 
seen when the analysis was performed using 100 segments.
In conclusion, the TVWA, TLA, and W/L index of the carotid artery can be assessed with high 
reproducibility at a fi eld strength of 3T. Thickness measurements of the carotid vessel wall 
at a fi xed position can be evaluated with good reproducibility in subjects without occlusive 
atherosclerotic plaques.
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To assess carotid artery vessel wall dimensions in patients at intermediate-to-high cardiovascu-
lar (CV) risk compared to healthy young control subjects with 3 Tesla MRI. As a second objective 
the MRI measurements were compared with those values obtained by ultrasonography. 
Materials and Methods 
Patients in Group 1 (n=28; age 61.8±4.64yrs) had intermediate-to-high CV-risk, whereas group 
2 (n=11; age 24.7±3.74yrs) consisted of healthy subjects. Mean wall thickness (MWT), wall area 
and lumen diameter, were measured in the left carotid artery using a black blood fast gradient 
MRI pulse sequence at 3 Tesla. Intima-media thickness (IMT) and lumen diameter were also 
measured by ultrasound in the same vessel segment.
Results 
Group 1 subjects had signifi cantly higher MWT and wall area as compared to group 2 
(1.40±0.30mm vs 0.87±0.07mm; p<0.001 and 1.90±0.61mm vs 0.96±0.11mm; p<0.001). MRI 
assessment of lumen diameters showed high agreement with US (intraclass correlation coef-
fi cient 0.882). Furthermore, signifi cant correlations were found between IMT and both MWT 
and wall area (r=0.84, p<0.001; 0.78, p<0.001, respectively). 
Conclusion 
MRI successfully discriminated vessel wall characteristics in intermediate and high risk patients 
from those in young healthy control subjects. MRI showed high dimensional precision with US 
as reference and signifi cantly correlated with IMT. 
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INTRODUCTION
Vessel wall assessment is increasingly used to improve cardiovascular risk stratifi cation. Ultra-
sonographic (US) evaluation of the carotid artery has been developed and yields a measure of 
the vascular intima-media complex. Intima media thickness (IMT) is an established marker of 
atherosclerosis.  IMT is related to cardiovascular risk factors (1;2), coronary atherosclerosis (3-5), 
and future cardiovascular events (6;7). Therefore, IMT is frequently used as an intermediate end-
point in clinical trials and is approved by the Food and Drug Administration for this purpose. 
Magnetic resonance imaging (MRI) is now emerging as an imaging modality for the assessment 
of carotid artery atherosclerosis. Several studies have addressed the potential of 1.5 Tesla MRI to 
assess carotid artery vessel wall characteristics (8-11). Recently, MRI at 3T has been validated as 
a reproducible technique to assess the carotid artery vessel wall (11). However, the use of MRI 
at 3T to discriminate between the vessel wall dimensions of patients at intermediate-to-high 
cardiovascular risk from normal subjects has not been extensively studied. 
Accordingly, the purpose of this study was to assess carotid artery vessel wall area characteristics 
in patients at intermediate-to-high cardiovascular risk versus those in healthy young subjects 
using 3 Tesla MRI. In addition, the MRI measurements of the vessel wall area and diameter were 
compared to those obtained by ultrasonography.
METHODS
Study Design & Subjects
The study was prospectively performed over a 1 year period. The study population was formed 
by 30 older male subjects attending our outpatient ward (group 1). These patients were treated 
in a primary prevention setting and had an intermediate to high cardiovascular risk as assessed 
using Framingham risk scores. The subjects of group 1 were contrasted to 11 young healthy 
volunteers (group 2). The US and MRI scans were performed by fully trained single observers, 
blinded for the results of the scan with the other imaging modality. Both observers were physi-
cians with at least 4 years of experience using the carotid artery scanning protocol. The time 
between ultrasound (US) and MRI examination was never more than 2 months. In 2 cases the MRI 
was not interpretable due to insuffi  cient quality resulting in 39 subjects for analysis. Informed 
consent was obtained and the study protocol was approved by the hospital ethics committee.
Magnetic Resonance Imaging Protocol
Magnetic resonance imaging was performed on a 3-Tesla scanner (Philips, Achieva, Best, The Neth-






Philips SENSE-fl ex-M surface coil was used for imaging. The left carotid artery was examined in all 
subjects. Three fast gradient echo sequence surveys were performed to localize the course of the 
common carotid artery. Subsequently, fi ve contiguous transverse slices with 2mm slice thickness 
were acquired, starting from 1cm proximal to the fl ow divider, thereby covering the most distal 
1 cm of the common carotid artery. A dual inversion recovery (black-blood), spoiled segmented 
k-space fast gradient echo sequence with spectral selective fat suppression was used for the acqui-
sition of transverse slices. Images were acquired in cardiac end-diastole at each RR interval using 
ECG triggering. The following imaging parameters were used: echo time 3.6ms, repetition time (TR) 
12ms, fl ip angle 45 degrees, and 2 signal averages were performed. A re-inversion slice thickness of 
3mm was used. The fi eld of view was 140mm. When using a matrix size of 306 the resulting voxel 
size was 0.46mm x 0.46mm x 2mm. Each MRI study took approximately 30 minutes depending on 
the cardiac frequency. All images were analyzed by a single observer with 4 years experience, using 
the VesselMASS software package, allowing manual tracing of vessel boundaries and automated 
quantifi cation of lumen diameter, wall area and mean wall thickness (12). Mean wall thickness 
(MWT) was calculated by averaging the mean thickness at all 5 slices of the common carotid artery. 
Vessel wall area (VWA) was quantifi ed by extracting the luminal area from the detected outer vas-
cular boundary at each slice. The sum of these 5 area values was used as the outcome parameter 
VWA. Figure 1 shows a representative example of an MRI scan of the carotid artery.
Ultrasound protocol
IMT measurement was performed using an Acuson Sequoia 512 (Siemens Medical Solutions, 
CA, USA) high-resolution ultrasound machine with an 8MHz linear transducer. One IMT-certifi ed 
sonographer (4 years of experience) performed all the ultrasounds. First, a transverse scan was 
performed for orientation, starting at the clavicle and moving cranially up to the mandible, hereby 
locating the height of the carotid bifurcation. Subsequently, longitudinal images were obtained. 
This technique allows visualization of two echogenic lines, separated by an anechoic space. It has 
previously been established that these lines indicate the blood-intima and the media-adventitia 
interfaces, and that the distance between the lines represents a reliable measure for IMT (13). The 
scan included visualization of the near and far walls of the left common carotid artery, at four angles 
of insonation (anterior, two antero-lateral projections and lateral). The caudal tip of the fl ow divider 
Figure 1. Representative example of 3-Tesla MRI image of the carotid artery of a 62-year old male 
subject. Black arrows indicate the carotid artery. Five contiguous transverse slices of 2mm, covering the 
most distal 1cm of the common carotid artery are shown.
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was used as the anatomical landmark to localize the most distal 1cm of the common carotid artery. 
Overall gain settings were kept at 0dB when possible. The sonographer was free to adjust the gain 
levels if necessary, within the limits of -7dB to 7 dB. The scan was recorded on sVHS video cassettes 
and digitalized for off -line analysis. IMT values were quantifi ed using computer aided automatic 
boundary detection where possible and manual adjustment where necessary. Analyses were done 
by a trained analyst, using the ASM II software package version 1.1364. IMT was defi ned as the 
average of the mean values of the common carotid artery, at all four angles. Lumen diameter was 
also determined at four angles and defi ned as the distance between the intima-lumen interface of 
the near wall and the lumen-intima interface of the far wall. Quantifi cation of all parameters was 
timed to coincide with cardiac end-diastole using an on-screen 3-lead ECG. 
Statistical analysis 
All data followed normal distribution, calculated by levels of skewness and kurtosis. All data 
are expressed as means ± SD. Comparisons between the groups were performed with inde-
pendent samples t tests. Correlations between US and MRI were calculated using Pearson’s 
correlation coeffi  cients. Bland-Altman analyses (14) and intraclass correlations coeffi  cients (ICC) 
were calculated and used to assess agreement of the two imaging modalities. Linear regression 
between IMT and MRI wall thickness were plotted to approach the MRI value corresponding 
to an IMT of 0.9mm, considered the clinically relevant cut-off  value (6).  P-values of <0.05 were 
designated as statistically signifi cant. 
Table 1: Subject characteristics and main outcome parameters
Variable Group 1 Group 2
N 28 11
age (yrs) 61.8 [±4.64] 24.7 [±3.74]*
Framingham CHD risk score (%/10yrs) 15.8 [±4.76] -
MWT; MRI (mm) 1.40 [±0.30] 0.87 [±0.07]*
VWA; MRI (cm2) 1.90 [±0.61] 0.96 [±0.11]*
mean IMT; US (mm) 0.86 [±1.60] 0.50 [±0.03]*
lumen diameter; MRI (mm) 7.00 [±0.80] 6.00 [±0.43]
lumen diameter; US (mm) 7.00 [±0.86] 5.96 [±0.34]
Values are expressed in means [±SD]. group1=older subset; group 2=young healthy volunteers. Data 
show the expected diff erences between the younger and the older group in vessel wall parameters. 
No diff erence was observed between MRI and US in measurement of lumen diameter, confi rming 
dimensional compatibility between the techniques. Asterisk (*) indicates statistically signifi cant diff erence 
between group 1 and 2 (p<0.001). 
CHD: coronary heart disease
IMT: intima-media thickness
MWT: mean wall thickness







A summary of the results is given in Table 1. The Framingham risk scores of group 1 subjects 
ranged from 6 to 29%/ 10 years. In young subjects the estimated cardiovascular risk is low to very 
low (<<5%/10 years) but diffi  cult to estimate as age puts substantial weight in the algorithms. 
MWT and VWA were signifi cantly higher in group 1 compared to group 2. IMT values were also 
signifi cantly higher in group 1 compared to group 2. MWT and VWA correlated strongly with 
IMT. A highly signifi cant correlation was observed for assessment of lumen diameters mea-
sured using the two modalities (Table 2). A Bland-Altman plot (fi gure 2) showed no signifi cant 
diff erence of US and MRI in measured lumen diameters. An acceptable variation around the 
mean (within 1.96 standard deviations) was observed without upward or downward bias. US 
and MRI assessment of mean lumen diameters showed high intraclass correlation for absolute 
Table 2: Bivariate correlations between main outcomes by MRI and US
Variable Pearson coeffi  cient (r) P-value
MWT vs. IMT 0.84 <0.001
VWA vs. IMT 0.78 <0.001
lumen diameter (MRI vs. US) 0.88 <0.001
The high correlations with IMT validate the use of these MRI parameters as surrogate markers for 
atherosclerosis
IMT: intima media thickness
MWT: mean wall thickness
VWA: vessel wall area
Figure 2. Bland-Altman plot of ultrasound and MRI values for lumen diameter. 
 
Data indicate a very high agreement between the two imaging modalities, shown by the mean line 
coinciding exactly with 0.0 and acceptable distribution within a range of 1.96 standard deviations (SD). No 
trend is seen in the distribution around the mean.
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agreement (0.882, p<0.001). Bland Altman analysis of MWT versus IMT showed MWT was on 
average 0.50 mm higher than IMT. A systematic upward bias was observed of MWT compared 
to IMT (paired sample T-test p<0.001). Figure 3 illustrates this upward tendency with increasing 
IMT+MWT (r=0.72 (p<0.001). Lastly, the regression analyses are given in fi gure 4 (MWT vs IMT) 
and 5 (VWA vs  IMT). Based on these data, the IMT cut-off  level of 0.9 mm is expected to cor-
respond with a MWT value of 1.45 mm and a VWA value of 2.00 cm2. 
DISCUSSION
The main fi nding of the current study is that MRI can successfully discriminate between vessel 
wall characteristics of intermediate to high risk asymptomatic patients versus young healthy 
subjects. Furthermore, 3 Tesla MRI showed excellent dimensional agreement with US, and MRI 
measurements of wall thickness and wall area correlated well with IMT.
We compared intermediate and high cardiovascular risk patients to healthy control subjects 
regarding MRI measured vessel wall characteristics. Thus, our results extend the previous fi nd-
ings of Underhill et al (15) and Mani et al (16). Underhill studied the potential of MRI in 28 
cases out of 43 patients with 16-79% carotid stenosis. Mani et al reported 17 patients with 
at calculated mean intermediate to high risk of 14% (range 6-31%). This risk may have been 
underestimated in this study as 30% of the patients had suff ered from cardiovascular events. 
Taken together, these studies have now clearly shown the discriminative potential of  MRI 
regarding vessel wall characteristics in intermediate to high risk patients either with carotid 
Figure 3. Bland-Altman plot of ultrasound and MRI values for carotid vessel wall thickness. 
Data indicates that MRI fi ndings for MWT are systematically higher than US values of IMT, shown by the 
mean line coinciding with 0.50. A signifi cant upward trend is seen in the distribution around the mean 
(r=0.72, p<0.001), implying the diff erence between US and MRI evaluation is more pronounced with 






stenosis (15), within intermediate risk patients (16) or in comparison to healthy young control 
subjects as shown in our study. In addition, the current fi ndings extend the results of the previ-
ous studies in 1.5T fi eld strength to 3T MR imaging. Compared to the abovementioned studies, 
the technical success rate of our 3T imaging protocol was excellent with 39 of 41 total scans 
being interpretable (95.1%).
Our study showed a high dimensional agreement between MRI and US for lumen diameter. 
High reproducibility of our protocol has previously been demonstrated (11). The current data 
add high dimensional precision of 3T MRI when using US as reference. This dimensional 
precision is of relevance when interpreting the relation between IMT and MWT.  As previously 
described, MWT signifi cantly correlated with IMT but was found to be consistently higher than 
IMT. This is in line with previous observations (15-17). This fi nding may refl ect the diff erence 
between the histopathological substrate of IMT (intima-media complex), and MWT  (total ves-
sel wall). Intriguingly, the degree of overestimation of MWT versus IMT (0.5 mm) we observed is 
reminiscent of the estimated thickness of the lamina adventitia. In patients with higher values 
Figure 4. Scatterplot of mean thickness; IMT (US) vs. MWT (MRI). 
Data demonstrate strong correlation between these thickness parameters (r=0.84). The dotted 




(______)  indicates linear regression line
(- - - -)  indicates 95% confi dence interval
(------)  indicates linear extrapolation lines 
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of MWT and IMT this overestimation was larger. It is noteworthy that very few published data 
are available on the exact thickness of the human carotid lamina adventitia in vivo. This points 
to the importance of the defi nition of cutoff  values for MRI in relation to cardiovascular risk 
assessment. In our hands values corresponding to established IMT cut-off  values could be 
approached using regression analysis (fi gure 4 and fi gure 5). However, we emphasize these are 
preliminary data and further studies are required to defi ne threshold values for MRI in relation 
to clinical cardiovascular events. 
Our study has limitations. We studied a limited number of young healthy control subjects. 
Extending this group would have increased the statistical power of the study. However, the 
level of signifi cance obtained is compatible with a low chance of a type II error. The coverage 
of the common carotid artery was limited to 1 cm. Three-dimensional MRI acquisition schemes 
have recently been proposed that allow more extensive coverage (18). Furthermore, IMT was 
assessed in longitudinal - MRI in cross-sectional samples. Nevertheless, the images obtained are 
acquired in an optimal technical setting for both techniques as also pointed out by Underhill 
et al. (15). 
Figure 5. Scatterplot of IMT (US) vs. VWA (MRI). Data demonstrate strong correlation between the 
parameters (r=0.78). The dotted extrapolation lines indicate that the clinically relevant cut-off  value of 
0.9mm for IMT corresponds with 2.00cm2 for VWA.
IMT=intima media thickness
VWA=vessel wall area. 
(______)  indicates linear regression line
(- - - -)  indicates 95% confi dence interval






In conclusion, MRI successfully discriminated vessel wall characteristics in intermediate and 
high risk patients from those in young healthy control subjects. MRI showed high dimensional 
precision with US as reference and signifi cantly correlated with IMT. Adding these characteris-
tics to its previously shown high reproducibility, the potential of 3T MRI in cardiovascular risk 
assessment and as clinical research tool is promising.
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To assess carotid artery vessel wall characteristics using three Tesla MRI in visceral obese male 
subjects with and without the Metabolic Syndrome (MS) compared to patients who recently 
suff ered from a ST-segment elevation myocardial infarction (STEMI).  
Methods
Black blood 3T MR vessel wall imaging was used to assess the carotid artery vessel wall character-
istics in male subjects with visceral obesity with and without the Metabolic Syndrome (VO+MS 
and VO respectively). A group of male patients with proven clinical relevant atherosclerosis, 
having recently (<1 month) suff ered from a STEMI, were chosen as comparator. In addition, a 
group of young healthy volunteers were assessed. As endpoints, carotid artery vessel wall area 
was used as a global marker of atherosclerotic disease burden and carotid artery maximum 
vessel wall thickness (MaxT) was used to address focal atherosclerotic vessel wall changes. 
Results
Maximum vessel wall thickness (MaxT) of the carotid artery bulb was highest in STEMI patients 
followed by VO+MS and VO and the healthy volunteers (diff erence between the groups 
P<0.001). MaxT in the carotid bulb of patients in VO+MS approached the level observed in 
STEMI patients and signifi cantly diff ered from VO patients (p≤0.01). Total vessel wall area of 
patients with STEMI, VO+MS and VO were signifi cantly increased compared to young healthy 
volunteers. 
Conclusions
The presence of Metabolic Syndrome in viscerally obese subjects, without manifest cardiovas-
cular disease or type 2 diabetes mellitus, is associated with increased maximum vessel wall 
thickness of the carotid bulb approaching the level observed in STEMI. Three Tesla MRI was 
successfully used in vascular phenotyping of visceral obese subjects.
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INTRODUCTION
Signifi cant proportions of western populations suff er from overweight or obesity.1-3 Obese 
subjects are at increased risk of developing cardiovascular disease and type 2 diabetes mel-
litus.4, 5 In large epidemiological studies, visceral obesity was shown to be a predictor of future 
cardiovascular events and cardiovascular mortality.6, 7 Viscerally obese subjects in particular, 
are considered to have metabolic abnormalities that contribute to the increased risk of car-
diovascular events.8-10 Visceral obesity, quantifi ed by waist circumference (WCR), has been 
identifi ed as an independent risk factor for insulin resistance, cardiovascular disease, hyperten-
sion and stroke.11-14  However, not all individuals with an increased waist circumference have 
disturbed metabolic profi les.15 Obese patients have been reported without insulin resistance 
and the related metabolic changes.16 The infl uence of the presence of metabolic disturbances 
in visceral obese subjects has not previously been studied in relation to atherosclerotic disease 
burden as measured by MRI. 
Magnetic resonance imaging (MRI) is a relatively new imaging modality used for the detection 
of atherosclerosis.17 MRI provides a circumferential view of the vessel of interest together with 
an accurate luminal dimensional characterization.18 MRI detected carotid artery vessel wall 
characteristics can be measured with good reproducibility.18-21 The validation of the technique 
requires further support, especially regarding the discrimination between subjects with diff er-
ent levels of cardiovascular risk and with respect to cardiovascular outcome. 
Accordingly, we set out to assess carotid artery vessel wall characteristics using three Tesla MRI 
in visceral obese male subjects with and without the Metabolic Syndrome (MS) and compared 
these to the characteristics as observed in patients who recently suff ered from ST-segment 
elevation myocardial infarction (STEMI).  
METHODS
Study design & Subjects
Sixteen patients with visceral obesity (VO), and 25 patients with visceral obesity and the meta-
bolic syndrome (VO+MS) were compared to a group of patients (n=12) who recently (<one 
month) suff ered from a ST-segment elevation myocardial infarction (STEMI). An additional 
group of young healthy volunteers (HV, n=12) was also assessed. The international diabetes 
federation (IDF) criteria were used to defi ne visceral obesity and the metabolic syndrome.22 
Subjects in the VO and the VO+MS group were without manifest clinical cardiovascular disease 
or type 2 diabetes mellitus (fasting blood glucose level <7 mmol/L).  The Framingham risk score 






by entering the lowest possible entry into the equation when the actual value of the variable 
was below the predefi ned minimum of the risk calculator. In all subjects, medical history, 
anthropometry and extensive laboratory assessments were performed within two weeks of 
MRI assessments. Statin use was defi ned as an exclusion criterion except in the STEMI group. In 
the STEMI group, MRI assessments were performed within 4 weeks after discharge to minimize 
the infl uence of statin use on the vessel wall characteristics. The study protocol was approved 
by the institutional review committee and all subjects gave informed consent.
3T Carotid Magnetic Resonance Imaging Protocol
Magnetic resonance imaging was performed on a 3T scanner (Philips, Achieva, Best, The 
Netherlands) using a standard Philips SENSE-fl ex-M surface coil as previously described and 
validated.18 In brief, the left carotid artery was examined in all subjects. After localization of the 
vessel using fast gradient echo sequence surveys, a total of ten contiguous transverse slices 
were acquired from the carotid bifurcation covering 2 cm of the carotid bulb and the com-
mon carotid artery from the fl ow-divider in the proximal (caudal) direction. A dual inversion 
recovery (black-blood), spoiled segmented k-space fast gradient echo sequence with spectral 
selective fat suppression was used for image acquisition using the following parameters: echo 
time 3.6 ms, repetition time (TR) 12 ms, pulse angle 45 degrees, and 2 signal averages were 
performed. A reinversion slice thickness of 3 mm was used. The fi eld of view was 140 mm. With 
a matrix size of 306, a voxel size of 0.46mm x 0.46mm x 2mm was obtained. Each MR study 
took approximately 30 minutes depending on the cardiac frequency. All images were analysed 
using VesselMASS software package, allowing for a semi-automated quantifi cation of various 
descriptive parameters of the vessel. After tracing all scan series, vessel wall area (VWA) was 
calculated by subtracting the luminal area from the outer contour area. Maximum vessel wall 
thickness (MaxT) was assessed for the carotid bulb region. 
Statistical analysis
Continuous variables are presented as mean values ± standard deviation or as medians and 
interquartile ranges if the assumption of normality was not met. Comparisons between groups 
were made by one-way ANOVA with post hoc least signifi cant diff erence (LSD) testing. For 
parameters that were not normally distributed, Kruskall-Wallis tests were performed. If Kruskall-
Wallis tests showed signifi cant diff erences between the groups, diff erences between individual 
groups were tested by Mann-Whitney tests. These p values were multiplied by 3 to correct for 
multiple testing.  Analyses were performed using SPSS version 16.0 (SPSS, Chicago, Illinois, 
USA). All analyses were two-sided, with a level of signifi cance of α=0.05.
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VO+MS (2) N=25 STEMI (3)
N=12
Age (y) 25.7 (6.1) 61.2 (4.6) 60.6 (5.5) 57.3 (4.9)














Statin use 0 (0%) 0 (0%) 0 (0%) 12 (100%)
AHM 0 (0%) 1 (6.3%) 10 (41.7%) 12 (100%)
Length (cm) 172.5 (12.6) 178.6 (7.1) 178.4 (6.9) 180.2 (5.1)





























































HbA1c (%) * † 4.7 (4.4-5.1)
3†
4.9 (4.7-5.3) 4.9 (4.6-5.3) 5.3 (5.0-5.4)
0†
Glucose (mmol/L) 4.67 (0.79) 4.74 (0.57) 5.15 (0.65) 5.17 (0.60)
Insulin (μU/ml) * § 5.5 (2.0-10.8) 6.5 (4.3-8.8) 8.0 (5.5-12.8) 8 (3.8-9.5)
hsCRP (mg/L) * § 0.93 (0.66-1.03) 1.09 (0.65-1.63) 0.98 (0.60-1.62) 1.94 (1.07-3.25)







Data are means with SD (in case of normal distribution) or medians with inter quartile range (in case of 
skewed distribution, indicated by *). Statistical diff erences are shown by symbols (†=p<0.05, ‡=p<0.01, 
§=p<0.001), and accompanying numbers (0-3) refer to the group to which the data in the cell are 
signifi cantly diff erent. ANOVA, Kruskall-Wallis or Pearson Chi-square p values are given in the fi rst 
column.||: patients on statins and treated intensively to reduce blood pressure. 
AHM: Antihypertensive medication. HV: Young healthy volunteers. VO: Viscerally obese patients. VO+MS: 
Patients with visceral obesity and the metabolic syndrome. STEMI: Patients with a recent ST-segment 
elevation myocardial infarction. NA: not applicable. RRD: Diastolic blood pressure. RRS: Systolic blood 








Clinical and laboratory characteristics of the study subjects are provided in Table 1. Mean 
(SD) waist circumference was not signifi cantly diff erent between VO and VO+MS patients, 
105.0 (8.7) vs. 106.8 (9.3) respectively. Similarly no statistically signifi cant diff erences were 
observed for systolic and diastolic blood pressure and total cholesterol levels between VO 
and VO+MS. The calculated cardiovascular risk (Framingham risk score) were signifi cantly 
higher in VO+MS compared to VO.  STEMI patients received intensive antihypertensive and 
lipid-lowering treatment since the onset of myocardial infarction. Framingham risk scores 
are not used for risk assessment in the secondary prevention setting and were therefore not 
calculated for STEMI patients.   
MRI assessments (table2)
Both VWA and MaxT were signifi cantly diff erent between the groups (p<0.001, see Table 2). 
MaxT of the carotid bulb region was highest in STEMI (2.28 ±0.40mm), followed by VO+MS, 
VO and HV. MaxT of VO+MS group (2.20 ±0.55mm) was signifi cantly higher than MaxT in VO 
(1.86 ±0.30mm, p≤0.05). MaxT was signifi cantly lower in HV compared to all groups. Figure 1 
illustrates MaxT and VWA values of the groups. 
For VWA no signifi cant diff erences were observed between STEMI, VO+MS and VO. VWA was 
signifi cantly lower in HV compared to all other groups (p<0.001 for all pair wise comparisons). 
DISCUSSION
This study demonstrates that the presence of Metabolic Syndrome in viscerally obese subjects, 
without manifest clinical cardiovascular disease and type 2 diabetes mellitus, is associated with 

























Data are means with SD. Statistical diff erences are shown by symbols (†=p≤0.05, ‡=p≤0.01, §=p≤0.001), 
and accompanying numbers (0-3) refer to the group to which the data in the cell are signifi cantly 
diff erent. ANOVA p values are given in the fi rst column. HV: Young healthy volunteers. VO: Patients with 
visceral obesity. VO+MS: Patients with visceral obesity and the metabolic syndrome. STEMI: Patients with 
ST-segment elevation myocardial infarction. MaxT: maximal vessel wall thickness. VWA: vessel wall area.
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increased maximum vessel wall thickness of the carotid bulb approaching the level observed 
in recent onset STEMI patients. Furthermore, three Tesla vascular MRI was successfully used to 
phenotype visceral obese subjects with diff erent metabolic profi les.
Visceral obesity increases the risk of  cardiovascular morbidity and mortality.6, 7 Metabolic 
abnormalities contribute to the increased risk of future cardiovascular events in visceral obese 
subjects.8-10 In this study, we demonstrate that not all visceral obese patients are equal, as focal 
atherosclerosis is less outspoken in subjects with visceral obesity alone compared to subjects 
with visceral obesity and the metabolic syndrome. Several factors could contribute to the 
pathogenesis of the observed diff erences between the groups. Systolic (142.1±17.3mmHg vs. 
151.6±17.8mmHg, p>0.05) and diastolic  blood pressure (88.7±8.7mmHg vs. 90.2±9.5mmHg, 
p>0.05) were not statistically signifi cantly diff erent between the groups. However, from large 
studies it is known that every mmHG counts on endpoints and the mean diff erence of 9 
mmHg may have a pathofysiological impact on vessel wall biology. As both groups (i.e. VO and 
VO+MS) had comparable values for waist circumference (105.9±8.7cm vs. 106±9.3cm, p>0.05) 
a possible explanation from the viewpoint of central obesity to explain the increased MaxT in 
VO+MS could be a diff erent pattern in adipose tissue distribution.  Adipose tissue distribution 
has been causally related to metabolic disturbances23 and patients with increased WCR due 
to expanded subcutaneous fat deposits have been reported with normal risk factor profi les.24 
Unfortunately, we are not informed about adipose tissue distribution in our study population. 
Another explanation for the observed diff erence in atherosclerotic disease burden could be dif-
ferences between groups in atherogenic dyslipidemia. Signifi cant diff erences were observed in 
triglyceride and HDL-cholesterol levels between the groups. VO+MS patients had signifi cantly 
higher triglyceride levels and lower HDL-cholesterol levels compared to VO patients. The more 
outspoken atherogenic dyslipidemia may have had a pathofysiological role in the observed 
increased MaxT in VO+MS. This is inline with the well known cardiovascular risk associated with 
elevated triglycerides and low HDL-cholesterol levels.25-27  
Figure 1. Diff erences between groups in vessel wall area and bulbus maximum vessel wall thickness. 





















*: p<0.05, **: p<0.001, NS: not signifi cant. VWA: vessel wall area. MaxT: maximal vessel wall thickness. HV: 
Young healthy volunteers. VO: Patients with visceral obesity. VO+MS: Patients with visceral obesity and 






At present, intima media thickness (IMT) measured by ultrasound is the most used and best vali-
dated non-invasive imaging modality for the study of atherosclerosis in the carotid artery.28-31 
MRI has now emerged as an alternative technique to assess atherosclerosis. Vascular MRI has 
high reproducibility,18 and it signifi cantly correlates with echographically measured IMT.32, 33 
However, the validation of vascular MRI is ongoing and steps in this regard are to show that 
MRI can discriminate between subjects at diff erent levels of cardiovascular risk, and to compare 
subjects at risk for atherosclerotic events with patients with established cardiovascular disease. 
Using 3T black blood MRI of the carotid artery, we were able to show that elevated serum 
C-reactive protein level was associated with increased measures of atherosclerosis 34 Using the 
same technique, we now addressed the question whether MRI could discriminate between vis-
ceral obese subjects with and without the metabolic syndrome and compared them to patients 
who recently suff ered a ST-segment elevation myocardial infarction. Three tesla MRI was able 
to discriminate vessel wall characteristics between these groups. Intriguingly, maximum vessel 
wall thickness of the carotid bulb was not signifi cantly diff erent between STEMI patients and 
VO+MS patients (p>0.05), and the absolute values of MAxT observed were very similar. If maxi-
mum vessel wall thickness refl ects focal atherosclerotic changes of the vessel wall34, this could 
imply that patients with VO+MS approach the level of atherosclerosis that associates with overt 
cardiovascular events whereas VO only patients have less pronounced atherosclerosis. This is 
in line with the observation that presence of atherosclerotic plaques predict cardiovascular 
events.35
Our study has limitations. First, the possible limited power due to a relatively small sample 
size may have resulted in a type II error with regard to the less pronounced diff erences in 
atherosclerotic disease burden. Nonetheless, statistically signifi cant diff erences were detected 
in MaxT of the carotid bulb between VO and VO+MS. The STEMI patients were all treated with 
statins and antihypertensive medication. This could have infl uenced the carotid artery vessel 
wall. However, we performed the MRI within 4 weeks of discharge, and none of these subjects 
were treated with these medications before STEMI-onset. Finally, the participants of this study 
were all males. These observations will have to be confi rmed in female populations. 
In conclusion, this study demonstrates that the presence of Metabolic Syndrome in viscerally 
obese subjects is associated with increased maximum vessel wall thickness of the carotid bulb 
approaching the level observed in recent onset STEMI patients. Finally, this study shows that 3T 
vascular MRI is able to discriminate vessel wall characteristics in patients with diff erent clinical 
profi les. 
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Visceral obesity (VO) is associated with an increased risk of cardiovascular disease. Elevated 
C-reactive protein (CRP) levels are associated with VO and cardiovascular disease. After explor-
ing the relation between CRP and VO, we aimed to evaluate the VO independent relation 
between CRP and carotid atherosclerosis.
Methods and results
The prevalence of infl ammation was evaluated in 439 male subjects with VO without type 2 
diabetes and manifest cardiovascular disease. Waist circumference signifi cantly correlated with 
CRP (r: 0.20, p < 0.001). However, 18.2% of patients in the waist circumference group 94–102 
had elevated CRP levels while 9.6% of patients in the waist circumference group >118 cm had 
low CRP levels. From the 439 subjects, 40 subjects were prospectively selected for MRI assess-
ment of carotid atherosclerosis and visceral and subcutaneous adipose tissue distribution in a 
case–control setting matching for age and waist circumference. Twenty male subjects with age 
>50 years with CRP levels >2.5 mg/L (CRP+) were compared to 20 controls with CRP levels <1.8 
mg/L (CRP−). Maximum vessel wall thickness in CRP+ was signifi cantly higher both in the com-
mon carotid artery (15%, p < 0.01) and the bulb region (18%, p < 0.01). The distribution of fat 
in visceral and subcutaneous deposits was not signifi cantly diff erent between CRP+ and CRP−.
Conclusion
Elevated CRP levels are associated with signifi cantly increased maximum vessel wall thickness 
independent of VO and of MRI measured adipose tissue distribution, both in the common 
carotid artery and the carotid bulb.
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INTRODUCTION
Obesity is associated with increased risk of cardiovascular disease, type 2 diabetes mellitus and 
mortality. Viscerally obese subjects in particular, are considered to have metabolic abnormali-
ties that contribute to the increased risk of future cardiovascular events.1-3 The amount of vis-
ceral adipose tissue has been shown to correlate with metabolic cardiovascular risk factors.4-6 
However, not all individuals with an increased waist circumference (WCR) have disturbed 
metabolic profi les.7 Obese patients have been reported without insulin resistance and the 
related metabolic changes.8 
Plasma levels of C-reactive protein (CRP), a marker of the systemic infl ammatory state, is associ-
ated with obesity and visceral obesity (VO).9-11 The highest CRP levels were observed in obese 
patients with a selective excess of visceral adipose tissue.11 Both CRP and VO have predictive 
potential regarding future cardiovascular events.12, 13 The extent of systemic infl ammation may 
also vary considerably in obese subjects, similar to the variability in the metabolic profi les. Due 
to the association between VO and CRP levels, assessment of the independent contribution of 
CRP versus VO to cardiovascular disease and atherosclerosis is challenging. For instance, higher 
measures of intima media thickness (IMT) have been reported in association with elevated CRP 
levels14-16, but this eff ect was not independent of the infl uence of obesity.
Therefore, in the present study, after exploring the relation between infl ammation and VO, 
we aimed to evaluate the relation between CRP and carotid atherosclerosis independent of 
the infl uence of VO. We hypothesize that elevated CRP levels would associate with increased 
measures of atherosclerosis. Magnetic resonance imaging at the fi eld strength of 3 T was used 
for the assessment of carotid atherosclerosis.
MATERIALS AND METHODS
Study design and subjects
A total of 801 men above 50 years of age were recruited through the local media. The inclusion 
criterion was a WCR above 94 cm. Exclusion criteria were type 2 diabetes mellitus, manifest 
cardiovascular disease, use of statins, non-steroidal anti-infl ammatory drugs, severe obesity 
(BMI > 40 kg/m2), and contraindications for MRI. A group of 439 subjects met the criteria and 
were included in the study. Figure 1 demonstrates the fl ow diagram of the screening and selec-
tion process. Four diff erent strata were defi ned for both CRP levels (CRP ≤ 1 mg/L, 1 < CRP < 
1.8 mg/L, 1.8 ≤ CRP < 3 mg/L, and CRP ≥ 3 mg/L) and WCR (94–101 cm, 102–109 cm, 110–117 






were addressed. The study protocol was approved by the institutional review committee and all 
subjects gave informed consent. The study had no external funding source.
CRP and the vessel wall
To evaluate the VO independent relation between CRP and atherosclerosis a case–control 
design was used in 40 subjects matched for age, WCR and gender. The subjects were prospec-
tively retrieved from the total study population (n = 439). 20 male subjects with hsCRP > 2.5 
mg/L (CRP+) were matched by age (maximum diff erence 1 year) and WCR (maximum diff erence 
2 cm) to 20 male control subjects with hsCRP < 1.8 mg/L (CRP−). The subjects were evenly 
selected across the WCR-strata. In each WCR-stratum fi ve subjects with high CRP levels were 
matched to fi ve controls with low CRP levels. CRP was measured twice to exclude outliers. In 
addition to the exclusion criteria of the study, none of the subjects were current smokers or had 
a familial history of premature cardiovascular disease.
Anthropometric and laboratory assessments
Medical history and physical examination including anthropometry and blood sampling were 
performed on the same day. Blood pressure was assessed using an automatic blood pressure 
monitor (Omron 705IT, Hoofddorp, The Netherlands). Three measurements were averaged 
for use in the analysis. Blood samples were collected after a 12-h overnight fast for chemical 
and haematological laboratory assessments. The high-sensitive CRP assay was performed 
with the Tina Quant C-reactive protein (latex) high sensitive assay (Roche, Basel, Switzerland). 
Figure 1. Flow chart of the screening and selection process.
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Participants with CRP levels above 15 mg/L were regarded as having an inter-current infection 
and were not included in the assessments. Insulin was determined in heparinised plasma using 
a solid-phase, two-site chemiluminescent immunometric assay carried out on an Immulite 
2500 (DPC, Los Angeles, USA).
Magnetic resonance imaging protocol
Carotid imaging
Magnetic resonance imaging was performed on a 3 T scanner (Philips, Achieva, Best, The 
Netherlands) as previously described and validated.17 In all subjects, the left carotid artery was 
examined. After localization of the carotid artery, 10 contiguous transverse slices were acquired 
covering 2 cm of the carotid bulb and the common carotid artery. A dual inversion recovery 
(black-blood), spoiled segmented k-space fast gradient echo sequence with spectral selective 
fat suppression was used for image acquisition with the following parameters: echo time 3.6 
ms, repetition time (TR) 12 ms, pulse angle 45°, and 2 signal averages were performed. ECG 
triggering was used for data acquisition at each RR interval at end diastole. Reinversion slice 
thickness was 3 mm. The fi eld of view was 140 mm. With a matrix size of 306, a voxel size of 0.46 
mm × 0.46 mm × 2 mm was obtained. Images were analysed, using the VesselMASS software 
package developed at our institution. Disease burden was assessed by the following derived 
parameters: Maximum vessel wall thickness in the common carotid artery (commonMVT) and 
the carotid bulb (bulbMVT). Vessel wall area in the common carotid artery (commonVWA), 





Maximum vessel thickness refl ects the local formation of an atherosclerotic plaque both in the common 
carotid artery (A and B) and the carotid bulb (C and D). Elevated maximum vessel thickness measurements 
(A = 2.52 mm and C = 3.73 mm) are associated with atherosclerotic plaque formation in comparison to 






the carotid bulb (bulbWVA) and total vessel wall area (totalVWA = commonVWA + bulbVWA). 
Maximum vessel wall thickness can refl ect the degree of focal plaque formation (Figure 2), 
while vessel wall area provides more global information on the extent the atherosclerotic 
process (Figure 3).
Adipose tissue imaging
Subjects were positioned in the magnet in a supine position. The body coil was used for obtain-
ing the images. A sagittal single shot gradient echo sequence survey scan was used for the 
imaging of the vertebral column in the lumbar region. Subsequently, a second single shot 
gradient echo sequence in the transversal plane was used for obtaining three contiguous slices 
of 10 mm without angulations with the following parameters: echo time 3.7 ms (TE), repetition 
time7.5 ms (TR), pulse angle 45°, and 2 signal averages were performed. The slices were centred 
at the intervertebral disk level between the fourth and fi fth lumbar vertebra. The images were 
obtained with three breath holds of 6 s. The fi eld of view was 500 mm. A voxel size of 1 mm × 1.3 
Figure 3. Vessel wall area. 
A 
B 
Vessel wall area provides global information on the extent of the atherosclerotic disease burden. An 
elevated total vessel wall area measure (A = 5.53 cm2) refl ects more extensive global disease progression 
as seen by wall thickening and asymmetry, in comparison to lower area measures (B = 3.01 cm2).


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































mm × 10 mm was obtained. Images were assessed using the MASS software package allowing 
a semi-automated detection of subcutaneous (SAT) and visceral adipose tissue (VAT) area.
Statistical analysis
Continuous variables are presented as mean values ± standard error or as medians and inter-
quartile ranges if the assumption of normality was not met. Categorical variables are presented 
as frequencies (%). As CRP levels were not normally distributed they were logarithmically 
transformed for bivariate correlation analysis. Comparisons between continuous variables 
were performed with independent samples t-tests or Mann–Whitney U-tests when not nor-
mally distributed. Testing for trends relating WCR to CRP strata in Table 2 was performed using 
the Chi-squared (χ2) test. Correlations of baseline CRP levels with patient-related factors were 
analyzed with bivariate correlation analysis (Pearson’s or Spearman’s correlation depending on 
distribution) and stepwise multiple regression analysis. In the multiple regression analysis, the 
eff ect of CRP and covariates was assessed with logarithmically transformed MRI derived vascu-
lar endpoints as dependent variables. The covariates used were those metabolic parameters 
that were potentially (p < 0.1%) diff erent between the CRP+ and CRP− group.
In a post hoc exploration, in order to assess if CRP was associated with vessel wall characteristics 
in the low and intermediate Framingham risk groups (Framingham score ≤10%, and 11–20%, 
respectively) vessel wall characteristics were plotted for tertiles of CRP and analysed using 
ANOVA or Kruskal–Wallis as appropriate. Diff erences were observed only in the normally 
distributed variables (thus after ANOVA) and were further analysed by independent samples 
t-tests. Analyses were performed using SPSS Version 12.01 (SPSS, Chicago, IL, USA). All analyses 
were two-sided, with a level of signifi cance of α = 0.05.
Sample size calculations were diffi  cult due to the lack of data for 3 T MRI. The sample size for 
this study was estimated at 40 participants (20 in each group) based on a previous report using 
less sensitive 1.5-T MR carotid artery imaging where MRI was calculated to be able to detect a 
10% change in vessel wall volume in a study with 14 participants per group with a power of 
80%, p < 0.05.18
RESULTS
Patient characteristics
From the 801 responding subjects, 439 were eligible for further analysis (Figure 1). Mean age 
of the group was 60.5 years, mean WCR 107.0 cm and CRP 2.31 mg/L. The characteristics of 
the subjects are summarized in Table 1. This table also provides detailed information on the 
characteristics of the subjects as grouped by WCR (WCR-strata) and by CRP levels (CRP-strata). 
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Table 2. The distribution of subjects along CRP strata according to the diff erent waist circumference 
strata.
CRP ≤ 1 1<CRP< 1.8 1.8<CRP< 3 3≤CRP Total
WCR 94-101cm (count, % of  total 
439 subjects)
%  of the subjects in this waist  
group with this CRP level 
%  subjects in this CRP group 
















WCR 102-109cm (count, % of  
total 439 subjects)
%  of the subjects in this waist  
group with this CRP level 
%  subjects in this CRP group 

















WCR 110-117 (count, % of  total 
439 subjects)
%  of the subjects in this waist  
group with this CRP level 
%  subjects in this CRP group 
















WCR≥118 (count, % of  total 439 
subjects)
%  of the subjects in this waist  
group with this CRP level 
%  subjects in this CRP group 
















% subjects in CRP group














As expected, increasing WCR was associated with signifi cantly increasing systolic (p < 0.001) 
and diastolic (p < 0.001) blood pressure, fasting blood glucose (p < 0.001), triglycerides (p < 
0.01) and CRP levels (p < 0.001). With increasing CRP, signifi cantly higher measures of WCR (p 
< 0.001), body weight (p < 0.001) and BMI (p < 0.001) were found. HDL-cholesterol levels were 
signifi cantly lower in groups with increasing CRP levels (p = 0.01). Other variables known from 
the metabolic syndrome were not signifi cantly diff erent between CRP-strata.
Infl ammation and visceral obesity
WCR signifi cantly correlated with CRP levels (r: 0.20, p < 0.001). The distribution of subjects 
along WCR-strata and CRP-strata is illustrated in Table 2. The relation between WCR and CRP 
is further illustrated in Figure 4: 39.9% of the subjects with WCR 94–101 cm have CRP levels 
less than 1 mg/L, while 48.1% of subjects with WCR ≥ 118 cm were found to have CRP levels 
higher than 3 mg/L. Furthermore, in the two lowest WCR-strata (94–101 and 102–109 cm) most 
subjects (61.5%) had CRP levels below 1.8 mg/L, whereas in the two highest WCR-strata most 
subjects (64.5%) had CRP levels exceeding 1.8 mg/L. However, 18.2% of patients in WCR group 
94–102 had increased CRP levels while 9.6% of patients in the highest waist group had low CRP 
levels.
Analyzing the data from CRP-perspective, the percentage of individuals signifi cantly decreased 
with increasing WCR in the 2 lowest CRP-strata. This pattern was less prominent within the third 
CRP stratum (1.8–3.0 mg/L) and absent in the highest CRP-stratum (≥3 mg/L). Thus, patients 
with high CRP levels were more or less randomly distributed over the WCR strata. The trends 
in patterns of distribution of subjects were statistically signifi cant (p < 0.001). Subsequently, 
from each WCR-stratum subjects with low and high CRP levels were prospectively matched for 
further MRI evaluation as described in the materials and methods section.
Figure 4. Distribution of subjects with varying CRP levels across diff erent waist circumference strata.
CRP 1 mg/L 
1 mg/L < CRP < 1.8 mg/L 
1.8mg/L  CRP < 3mg/L 
CRP 3 mg/L 
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CRP and the vessel wall
Vessel wall characteristics were analysed in CRP+ versus CRP−. The clinical characteristics of the 
two groups are summarized in Table 3. By defi nition, CRP levels signifi cantly diff ered between 
the two groups. The CRP+ and CRP− groups did not diff er regarding age (60.4 years vs. 60.3 
years) and WCR (111.3 cm vs. 110.9 cm). Further anthropometric and metabolic variables 
including blood pressure were similar in both groups except for triglyceride levels (p = 0.01).
3T MRI assessments (Table 4)
Maximum vessel wall thickness was signifi cantly higher in CRP+ compared to CRP−, both in the 
common carotid artery (15%) and the carotid bulb region (18%). Median and the inter-quartile 
range for vessel wall thickness were 1.64 mm [1.33–1.85] in CRP+ versus 1.34 mm [1.26–1.59] 
in CRP− (p < 0.01) in the common carotid artery; the respective values in the carotid bulb were 
2.14 mm [1.89–2.54] versus 1.83 mm [1.63–1.99] (p < 0.01). Diff erences in vessel wall areas did 
not reach statistical signifi cance, although the measurements were consistently higher in the 
CRP+ group for all area endpoints. No signifi cant diff erences were observed in VAT and SAT 
between the two groups. Log CRP signifi cantly correlated with all MRI derived measures of 
atherosclerosis. Further correlations between log CRP and VAT or SAT were not explored as they 
could have been confounded by the matching strategy (Table 4).
Table 3. The clinical characteristics of the two groups with varying CRP levels matched by WCR and age 
for MRI assessment
CRP + mean (S.D.) CRP − mean (S.D.) p-Value 
Age (years) 60.4 (5.3) 60.3 (5.2) 0.97
WCR (cm) 111.3 (9.7) 110.9 (9.8) 0.89
Body weight (kg) 100.6 (10.45) 97.8 (13.80) 0.47
BMI (kg/m2) 30.8 (3.3) 30.4 (3.5) 0.76
Systolic BP (mmHg) 149.8 (15.8) 154.2 (18.3) 0.43
Diastolic BP (mmHg) 90.7 (8.44) 93.1 (10.1) 0.42
 CRP 1 (mg/L)a 4.95 (3.44–5.75) 0.88 (0.58–1.08) <0.001
CRP 2 (mg/L)a 4.20 (3.25–5.45) 0.73 (0.54–1.41) <0.001
HBA1c 4.9 (0.46) 5.02 (0.42) 0.41
FBG (mmol/L) 5.32 (0.51) 5.02 (0.68) 0.12
Cholesterol (mmol/L) 5.83 (1.14) 5.46 (0.78) 0.24
TG (mmol/L)a 1.76 (1.27–2.16) 1.27 (0.94–1.58) 0.01
HDL (mmol/L) 1.29 (0.35) 1.48 (0.37) 0.10
LDL (mmol/L) 3.69 (0.92) 3.39 (0.69) 0.25
Insulin (mU/L)a 12.00 (4.71–18.75) 7.00 (5.00–10.00) 0.06
HOMAa 1.6 (0.60–2.38) 0.9 (0.61–1.30) 0.10
Framingham 13.65 (5.40) 12.60 (5.90) 0.56
WCR: waist circumference. BMI: body mass index. BP: blood pressure. FBG: fasting blood glucose. HOMA: 
HOMA insulin resistance index.






Multiple regression analysis was performed with maximum vessel wall thickness as dependent 
variable and CRP, triglycerides, and HOMA insulin resistance index as covariates as described in 
the methods section. The model signifi cantly explained 32% (p = 0.001) of variance for the com-
mon carotid artery maximum vessel wall thickness with CRP (β: 0.02 [0.009, 0.028]) and HOMA 
(β: −0.02 [−0.039, −0.003]) as signifi cant explanatory variables. No interactions were observed 
between HOMA and CRP. For the carotid bulb maximum vessel wall thickness the model could 
explain 18% of the variance observed (p < 0.01) with CRP (β: 0.02 [0.006, 0.032]) as signifi cant 
determinant of the model. The multiple regression analysis was repeated with CRP, HDL, and 
HOMA as covariates and MRI thickness measurements as dependent variables. HDL did not 





p-Value Correlation log CRP 
r (p-value)
CommonMVT (mm)a 1.64 (1.33–1.85) 1.34 (1.26–1.59) <0.01 0.47 (<0.01)
BulbMVT (mm)a 2.14 (1.89–2.54) 1.83 (1.63–1.99) <0.01 0.50 (<0.01)
CommonVWA (cm2) 1.79 (0.40) 1.60 (0.35) 0.12 0.45 (<0.01)
BulbVWA (cm2) 2.78 (0.49) 2.61 (0.61) 0.33 0.34 (0.03)
TotalVWA (cm2) 4.58 (0.78) 4.21 (0.91) 0.18 0.42 (<0.01)
VAT (cm2) 493.2 (143.7) 472.3 (200.4) 0.71 b
SAT (cm2) 931.0 (317.6) 848.3 (288.7) 0.39 b
MVT: maximum vessel thickness. VWA: vessel wall area. TotalVWA: sum of commonVWA and bulbVWA. VAT: 
visceral adipose tissue. SAT: subcutaneous adipose tissue.
a  Skewed distribution, data are presented as median (inter-quartile range), correlations were assessed 
using Spearman’s correlation coeffi  cients.
b  Not performed as it could have been confounded by the matching strategy.
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contribute signifi cantly to the models. The obtained models were identical to those with CRP, 
triglycerides and HOMA as covariates. The models demonstrate that CRP remained a signifi cant 
explanatory variable for the maximum vessel thickness both the common carotid artery and 
the bulb region when adjusted for HOMA, HDL and triglyceride levels.
CRP and the vessel wall in the intermediate cardiovascular risk population
In a post hoc analysis the relation between CRP and vessel wall characteristics was explored in 
relation to calculated cardiovascular risk according to the Framingham risk score. Within the inter-
mediate risk group, Total VWA was signifi cantly higher in the highest versus lowest tertile of CRP: 
4.91 cm2 versus 3.83 cm2 (p < 0.01), see Figure 5. This eff ect was also observed for the bulb region: 
3.00 cm2 versus 2.35 cm2 (p < 0.01). VAT and SAT were not signifi cantly diff erent between the ter-
tiles of CRP in the intermediate risk group. Within the low cardiovascular risk group the obtained 
measures of vascular characteristics did not diff er signifi cantly between the tertiles of CRP.
DISCUSSION
This study demonstrates that elevated CRP levels are accompanied by signifi cantly higher 
maximum vessel wall thickness both in the common carotid artery and the carotid bulb inde-
pendent of VO and of MRI measured adipose tissue distribution.
Increased CRP levels have been associated with diff erent measures of obesity.9-11, 19 The magni-
tude of this eff ect is typically reported to be in the range of r = 0.50–0.60.14, 20 This is in contrast 
to the weaker relation (p: 0.20) observed in our study. We studied viscerally obese subjects only 
while subjects with a normal waist girth were also included in the previous studies. This broader 
inclusion range may have contributed to higher correlation coeffi  cients reported. Lower p 
values (r = 0.37) have recently been reported in an obese population.21 The relation between 
CRP and WCR can be appreciated using Table 2. The majority (61.5%) of the least obese subjects 
(VO stratum 1 and 2) have a CRP level in the range 0–1.8 mg/L while 64.5% of the subjects in 
the two highest VO strata have CRP levels ranging from 1.8 to 8.53 mg/L. Interestingly, high 
CRP levels were also observed in less obese subjects. This undoubtedly has weakened the 
correlation between VO and CRP. The subjects with the highest CRP levels were more or less 
evenly distributed across the diff erent waist circumference strata suggesting that VO was not 
the only driving force behind infl ammation in some of these subjects. A possible explanation 
for these observations could be the inter-individual diff erences in infl ammatory repertoires and 
responsiveness. Timpson et al. for instance, have pointed to the potential genetic contribution 
to variation in CRP levels.22 To account for intra-individual variation, CRP levels were measured 
twice in our study. Subjects with elevated CRP levels (>15 mg/L) were excluded. In addition 






consisted of white Caucasian subjects. The median CRP level within a white Caucasian popula-
tion was shown to be 2.3 mg/L.23 This CRP level was used to defi ne the rounded-up threshold of 
2.5 mg/L for CRP in our study. Changing the threshold of CRP to 2.3 mg/L neither infl uenced the 
vessel wall outcomes of the study; nor did reanalysis based on the cut-off  value of 3.
We used magnetic resonance imaging at the fi eld strength of 3 T for the assessment of ath-
erosclerosis in this study. The precision and reproducibility of the technique in quantifying total 
plaque volume and disease burden has been previously reported by our group and others.17, 24, 
25 The accuracy of measurements at the ultra high fi eld strength of 3 T is due to the considerable 
increase in signal to noise ratio compared to 1.5 T, which in turn can be traded for a better 
in-plane resolution of the images. This has been demonstrated by the improved detection of 
complex atherosclerotic plaques as validated with histology26, and improved image quality of 
the carotid artery at the fi eld strength of 3 T.27
Our observation that elevated CRP levels are accompanied by higher maximum vessel wall 
thickness independent of VO extends previous fi ndings using other imaging modalities. An 
association has been observed between CRP levels and IMT as measured by ultrasonogra-
phy.14-16 In contrast to our study, the correlation between CRP and IMT may not have been 
independent from obesity or metabolic dysregulation such as dyslipidemia and insulin resis-
tance.14-16 In healthy children, higher CRP levels were shown to be associated with more exten-
sive IMT thickening and disturbed endothelial function.15 The children with higher CRP levels 
had a signifi cantly higher body mass index. Again the obesity-independent relation between 
CRP and atherosclerosis could not be fully appreciated. To overcome this we carefully matched 
the CRP+ and CRP− groups for age and WCR. Furthermore, the subjects were evenly selected 
across WCR strata to cover a broad range of VO. Metabolic profi les (Table 3) were very similar in 
CRP+ and CRP− except for fasting triglyceride levels. In a multiple regression analysis adjusting 
for potentially confounding factors such as triglycerides and HDL, CRP remained a signifi cant 
independent predictor of vessel wall thickness.
It could be argued that matching by waist circumference would not automatically have resulted 
in successful matching for visceral and subcutaneous fat deposits. As adipose tissue distribu-
tion is causally related to metabolic disturbances28, diff erences in the extent of adipose tissue 
deposits between the groups would have infl uenced the study observations. The importance 
of adipose tissue distribution is further illustrated by reports of normal risk factor profi les in 
patients with increased WCR due to expanded subcutaneous fat deposits.29 Therefore we 
studied adipose tissue distribution by MRI. We did not observe diff erences in adipose tissue 
distribution between the visceral and subcutaneous depots in CRP+ versus CRP−. Thus, the 
observed diff erences in vessel wall thickness are independent of adipose tissue distribution 
between subcutaneous and visceral deposits.
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A possible additive role of CRP in the prediction of future cardiovascular events has been dem-
onstrated in subjects at intermediate risk according to the Framingham score.30 In a post hoc 
analysis, we explored the relation between CRP levels and the extent of atherosclerotic disease 
burden in this group. Vessel wall areas (total and in the carotid bulb) signifi cantly diff ered 
between the highest versus the lowest tertiles of CRP within the intermediate risk patients. 
Intriguingly, vascular wall areas in the lowest CRP tertiles were very similar independent of the 
Framingham risk group (Figure 5). Thus, absence of a low grade infl ammation as measured by 
CRP was associated with limited atherosclerotic carotid vessel wall thickening as measured by 
MRI regardless of the calculated cardiovascular risk. These observations support reports show-
ing that CRP levels may add to risk stratifi cation within intermediate risk patients.30
The restricted number of participants in our MRI-study may have posed a limitation on detect-
ing other diff erences in atherosclerotic disease burden. In other words, only prominent eff ects 
might have been detected and less pronounced diff erences might have remained unobserved. 
This is in line with the observation that all vessel wall parameters signifi cantly correlated with 
log CRP. If so, the impact of CRP on atherosclerotic burden in the setting of VO may be larger 
than now described. Furthermore, design of the study should be taken into account. Matching 
the participants by WCR was necessary to eliminate VO from the “CRP–atherosclerosis” equa-
tion. The population assessed is therefore not a random sample from a general population and 
does not represent it (see Table 2).
In conclusion, we demonstrated that elevated CRP levels are associated with signifi cantly 
increased maximum vessel wall thickness both in the common carotid artery and the carotid 
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INTRODUCTION
Apolipoprotein CI (ApoCI) is an apolipoprotein mainly present on high-density lipoprotein 
(HDL) and postprandial on triglyceride-rich lipoproteins (TRLs). ApoCI infl uences many proteins 
involved in the remodeling of lipoproteins in plasma.1-6 In addition, ApoCI inhibits the ApoE-
mediated binding of VLDL and chylomicrons to the LDL receptor and to the LDL receptor-related 
protein (LRP).7 Recently, an important role of ApoCI in the modulation of the infl ammatory 
response was revealed in vitro and in mice.8 Therefore, as a possible link between lipid metabo-
lism and infl ammation, ApoCI may have the potential to contribute to the pathophysiology of 
atherosclerosis. Recent experimental data provided evidence that ApoCI augments the devel-
opment of atherosclerosis in the setting of chronic infl ammation in mice.9 The contribution of 
ApoCI to atherogenesis in humans has been examined in a few studies. The postprandial ApoCI 
content of TRLs was found to correlate with intima-media thickness.10 In addition, men with 
early asymptomatic atherosclerosis had postprandial VLDL and chylomicron particles enriched 
with ApoCI.7 Noto et al.11 observed an association between the ApoCI content of VLDL and 
plaque size in subjects with carotid atherosclerosis.
We hypothesized that ApoCI has an adverse eff ect on atherosclerotic vessel wall characteristics 
in the presence of systemic infl ammation and mild dyslipidemia observed in the metabolic 
syndrome (MS).
METHODS
We studied 98 male subjects, aged 50–70 years, with the MS (defi ned using International Dia-
betes Federation criteria12). Exclusion criteria were presence of type 2 diabetes mellitus, overt 
cardiovascular disease, the use of statins, fi brates or non-steroidal anti-infl ammatory drugs 
(NSAIDs), a body mass index (BMI) above 40 kg/m2, contraindications for magnetic resonance 
imaging (MRI), and a plasma level of high-sensitive C-reactive protein (hsCRP) exceeding 15 
mg/L. The study protocol was approved by the Local Ethics Committee and all patients signed 
informed consent. Blood samples were collected after a 12-h overnight fast. Chemical and 
hematological laboratory assessments were performed in the hospital laboratory. Plasma 
concentrations of ApoCI and ApoCIII were determined using sandwich ELISAs specifi c for 
human ApoCI13  and ApoCIII.14, 15 MRI of the carotid artery was performed on a 3T scanner 
(Philips, Achieva, Best, The Netherlands) as previously described and validated.16 Images were 
analysed using VesselMASS software package. Ten images, covering 2 cm, were produced 
of the common carotid artery and bulbus. Vessel wall area (VWA) for common carotid artery 
(common VWA) and bulbus (bulbus VWA), and total VWA (common VWA + bulbus VWA) were 






vessel wall thickness (MVT) was measured by calculating, for common carotid artery and bulbus 
separately, the mean of the thickest of 6 equal segments per image. To address the question 
whether ApoCI levels are associated with increased atherosclerotic vessel wall characteristics in 
the presence of systemic infl ammation and mild dyslipidemia, the study subjects were divided 
into four groups according to the absence or presence of systemic infl ammation (as defi ned by 
an hsCRP level of <3 and ≥3 mg/L, respectively) and plasma ApoCI level (above or below the 
median value, 6.38 mg/dL). Plasma levels of ApoCIII, a protein with a similar distribution over 
lipoproteins and comparable to ApoCI in mass and structure, were measured as a negative 
control. Like ApoCI, ApoCIII is associated with VLDL and HDL, but it has no known interaction 
with infl ammation.8 Diff erences in baseline characteristics, laboratory parameters and vessel 
wall measurements were assessed by one-way analysis of variance (ANOVA). Post hoc least 
signifi cant diff erence (LSD) testing was performed for parameters that proved statistically 
signifi cant on ANOVA. Kruskall–Wallis tests with Mann–Whitney test for pairwise comparisons 
(p values were multiplied by 3 to correct for multiple testing) were performed for parameters 
that were not normally distributed. Correlations were calculated using Spearman’s rho.
RESULTS AND DISCUSSION
Clinical and laboratory parameters of the patients are given in Table 1. Between the four groups, 
diff erences were observed in BMI, total cholesterol, LDL-cholesterol, HDL-cholesterol and tri-
glyceride levels. ApoCI did not correlate with hsCRP (rho = −0.042; n.s.), and was positively cor-
related with total cholesterol (rho = 0.462; p < 0.001), LDL (rho = 0.224; p < 0.05), HDL-cholesterol 
(rho = 0.347; p < 0.001) and TG levels (rho = 0.339; p < 0.001). No signifi cant diff erences in vessel 
wall area and MVT of the common carotid artery were observed between the groups. The 
maximal vessel wall thickness of the carotid bulb, however, was signifi cantly increased in the 
subjects with both systemic infl ammation and ApoCI above the median (Figure 1). There was 
no association between ApoCIII levels and vessel wall parameters in the presence or absence 
of systemic infl ammation.
To further explore the relation between ApoCI and infl ammation, univariate variance analy-
sis was performed with maximal vessel wall thickness of the carotid bulb as the dependent 
variable. The variables added as covariates were the metabolic syndrome parameters (waist 
circumference, fasting blood glucose, systolic and diastolic blood pressure, HDL-cholesterol, 
triglycerides), and ApoCI and hsCRP, all as continuous variables. In this model a statistically 
signifi cant interaction between ApoCI and hsCRP was observed (Model: R2 = 0.18; p = 0.035; 
interaction of hsCRP with ApoCI: p = 0.027; B = 0.031; hsCRP: p = 0.045; B = −0.168, ApoCI p = 
0.06; B = −0.091). When ApoCIII was added to the model instead of ApoCI, no interaction was 
observed between ApoCIII and hsCRP.
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Thus, the observed signifi cant interaction of ApoCI and hsCRP on atherosclerosis persisted after 
correction for the components of MS. In an infl ammatory setting ApoCI has a diff erent relation 
to the vessel wall than when infl ammation is absent. This result is in line with the close asso-
ciation between ApoCI and infl ammation-driven atherosclerosis in experimental studies.9 MS 
patients may be especially vulnerable to ApoCI-mediated atherogenesis as the MS phenotype 
is characterized by changes in HDL and VLDL metabolism, and is frequently associated with 
low grade systemic infl ammation. Vessel wall area measures, and MVT of the common carotid 
artery, were not diff erent between the groups in our study. This should be appreciated when 
interpreting the data. In our patients, many of whom were in an early phase of atherogenesis 
given the exclusion criteria applied, high ApoCI and systemic infl ammation were associated 
Table 1. Clinical and laboratory parameters for the four patient groups (ApoCI < median and hsCRP < 3 (1); 















Age (y) 59.2 (5.4) 58.5 (5.5) 58.2 (5.5) 59.9 (4.6) Ns
BMI (kg/m2) 30.7 (3.5) 29.2 (3.3) 3*, 4# 31.9 (3.5) 2* 31.4 (3.6) 2# 0.041
SBP (mmHg) 154.4 (17.1) 152.8 (18.3) 150.3 (12.7) 155.2 (19.5) Ns
DBP (mmHg) 94.0 (8.2) 89.2 (7.8) 91.8 (8.0) 91.7 (9.5) Ns
FBG (mmol/L) 5.4 (1.0) 5.5 (0.8) 5.7 (0.5) 5.8 (1.0) Ns
TotChol (mmol/L) 5.45 (0.9) 2*, 4* 6.23 (0.9) 1*, 3+ 5.26 (0.8) 2+, 4+ 6.29 (0.9) 1*, 3+ 0.000
Calculated LDL 
(mmol/L)
3.42 (0.7) 4# 3.54 (0.3) 3.16 (0.6) 4* 3.93 (0.8) 1#, 3* 0.025
HDL (mmol/L) 1.08 (0.3) 2+, 
3*, 4#
1.37 (0.3) 1+ 1.30 (0.3) 1* 1.30 (0.3) 1# 0.001
Triglycerides 
(mmol/L)
2.07 (0.9) 2* 2.81 (1.2) 1*, 3 * 1.78 (0.8) 2* 2.35 (1.0) 0.004




















ApoCIII (mg/dL) 8.71 (3.8) 2*, 4# 12.23 (4.4) 1*, 3* 8.51 (3.6) 2*, 4# 11.16 (3.3) 1#, 3# 0.001
Total VWA (cm2) 4.74 (1.0) 4.71 (1.4) 4.61 (1.0) 5.00 (0.8) Ns
Common VWA 
(cm2)
1.81 (0.4) 1.84 (0.6) 1.83 (0.4) 1.93 (0.4) Ns
MVT Common (mm) 1.62 (0.3) 1.64 (0.4) 1.58 (0.2) 1.68 (0.3) Ns
Bulbus VWA (cm2) 2.93 (0.7) 2.87 (0.9) 2.78 (0.6) 3.07 (0.5) Ns
MVT Bulbus (mm) 2.15 (0.4) 4 
(p = 0.016)
2.22 (0.7) 2.06 (0.4) 4 
(p = 0.009)




Mean or median with standard deviation or inter quartile range (IQR) are given, values represent means 
unless indicated otherwise. p Values for pairwise diff erences given below the mean values (number: group 
to which the value is diff erent, #p < 0.05, *p < 0.01, +p < 0.001). SBP: systolic blood pressure. DBP: diastolic 







with increased MVT at the level of the carotid bulb. Intriguingly, this is an area where plaques 
typically develop. We propose the increased MVT observed in the carotid bulb refl ects early focal 
atherosclerotic changes. Our data are in line with studies relating ApoCI content on postpran-
dial VLDL or TRL’s to ultrasonographically assessed vessel wall abnormalities.7, 10 This includes a 
recent report on plaque size.11 Our data extend these observations to fasting ApoCI levels using 
MR as imaging modality. Performing contrast-enhanced MRI would enable studying plaque 
volume and plaque characteristics in addition to MVT, and could be an important extension 
to our 3T MRI protocol. The strong associations of ApoCI with plasma lipids hinder establish-
ing whether ApoCI per se has a causal role in the pathogenesis of atherosclerosis. However, 
ApoCIII, the negative control, was not associated with increased vessel wall measurements. The 
subjects studied are representative of a primary prevention population of men aged 50–70 
years, with metabolic syndrome, without diabetes or cardiovascular disease. The fi ndings in this 
study cannot be extrapolated to the general population. Studying subjects with diabetes may 
be especially interesting because of the strong relation between diabetes and infl ammation. 
Furthermore, studying the ApoCI concentration in fasting plasma, compared with studying the 
postprandial ApoCI content of VLDL, as described by Hamsten et al.10, may lead to an under 
estimation of the eff ect of ApoCI on atherosclerosis in the presence of infl ammation. Although 
further studies are needed, our results suggest that the recent experimental fi ndings linking 
ApoCI to atherosclerosis may be translated to the human setting, and that ApoCI contributes to 
plaque formation, provided an infl ammatory environment is present.
Figure 1. Maximal vessel wall thickness in the carotid bulb (mean with 95% confi dence interval) for 
the four groups (ApoCI < median and hsCRP < 3; ApoCI > median and hsCRP < 3; ApoCI < median and 
hsCRP ≥ 3; ApoCI > median and hsCRP ≥ 3).
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Patients with visceral obesity and elevated C-reactive protein (CRP) levels are regarded at 
increased cardiovascular risk even in the absence of Diabetes Mellitus. Since rosiglitazone alters 
fat distribution, and has anti-infl ammatory eff ects, we hypothesized it would prevent progres-
sion of atherosclerosis in men with visceral obesity and elevated CRP when given in addition to 
intensive lifestyle therapy.
Design
Double blind, placebo controlled randomized clinical trial.
Setting & Subjects
Single centre primary prevention setting.
116 non-diabetic men with visceral obesity and CRP levels ≥1.8mg/L.
Interventions
Daily therapy with 8mg rosiglitazone plus intensive lifestyle therapy or placebo plus intensive 
lifestyle therapy for 52 weeks. Patients underwent three tesla magnetic resonance imaging 
(MRI) to assess vessel wall characteristics of the carotid artery.
Results
The primary outcome, the median [interquartile range (IQR)] change in carotid-artery total 
vessel wall area, was 0.04[-0.24 to 0.38]cm² in the rosiglitazone-lifestyle group and 0.001[-0.25 
to 0.20]cm² in the placebo-lifestyle group (P=0.19). Of the secondary endpoints, median [IQR] 
maximum vessel wall thickness increased 0.071[-0.06 to 0.16]mm in the rosiglitazone-lifestyle 
group and non-signifi cantly decreased -0.009[-0.08 to 0.10]mm in the placebo-lifestyle group 
(P=0.16). Rosiglitazone-lifestyle and placebo-lifestyle reduced median [IQR] waist circumference 
by -7.5[-11 to -3.9]cm and -8.8[-13 to -5]cm and median [IQR] CRP levels by -0.87[-2.23 to -0.26]
mg/L and -0.53[-1.95 to 0.61]mg/L, respectively. MRI assessment of fat stores showed similar 
decrease in visceral adipose tissue, while waist and hip subcutaneous fat stores decreased more 
in placebo-lifestyle treated patients. 
Conclusion
Rosiglitazone did not prevent progression of atherosclerosis when given on top of intensive 
lifestyle therapy in men with visceral obesity and elevated C-reactive protein levels. 
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INTRODUCTION
Visceral obesity (VO) and elevated C-reactive protein (CRP) levels indicative of systemic infl am-
mation are independent risk factors for myocardial infarction1 and cardiovascular mortality.2, 
3 The fi rst step in the treatment of subjects with visceral obesity is lifestyle therapy. Intensive 
lifestyle therapy can prevent type 2 diabetes mellitus (DM2).4-6 Although, increased physical 
activity and a healthy diet are known to be benefi cial in patients with manifest coronary heart 
disease7, 8, the eff ect of intensive lifestyle therapy on intermediate endpoints of atherosclerosis 
has not been studied in visceral obese patients with elevated CRP levels. In addition to intensive 
lifestyle therapy, medication that alter fat distribution and decrease systemic infl ammation 
may have an additive potential to prevent progression of atherosclerosis.   Rosiglitazone is a 
peroxisome-proliferator-activated receptor γ (PPARγ) agonist that alters fat distribution and 
modulates metabolic and infl ammatory gene repertoires.9-11 More specifi cally, it redistributes 
fat from visceral to peripheral stores and decreases CRP levels.12, 13 Given these characteristics, 
we hypothesized rosiglitazone would prevent progression of atherosclerosis in men with vis-
ceral obesity and elevated CRP levels, when given in addition to intensive lifestyle therapy. In 
line with this hypothesis, rosiglitazone reduced the progression of atherosclerosis as measured 
by ultrasonography yielding measures of carotid artery intima media thickness (IMT) in patients 
with DM2.14 
In this study, we sought to determine whether the daily administration of 8mg of rosiglitazone 
in combination with intensive lifestyle therapy could prevent the progression of atherosclerosis 
in non-diabetic patients with visceral obesity and elevated CRP levels. In our study, called “A 52 
week double-blind randomized controlled trial comparing the eff ect of Rosiglitazone versUs 
placeBo on the prevENtion of progression of atheroSclerosis in high risk patients without 
diabetes (RUBENS) trial” we used three Tesla magnetic resonance imaging (MRI) of the carotid 
artery vessel wall as a surrogate measure to assess the progression of atherosclerosis. 
MATERIALS AND METHODS
Study design
Our prospective randomized double-blind placebo controlled trial was performed at LUMC, 
Leiden, The Netherlands as a single centre study. Patients provided written informed consent. 
The study was approved by the institutional review committee and was conducted according 
to the principles expressed in the Declaration of Helsinki. Men of 50 years or older were eligible 
to participate in the study if  a waist circumference ≥94cm and a CRP levels of 1.8mg/L or higher 
was present. The cut-off  value of 1.8mg/L for CRP was chosen based on the previously reported 






the presence of either at least two other metabolic syndrome criteria according to the IDF defi -
nition16 or the presence of premature cardiovascular disease in a fi rst degree family member. 
Exclusion criteria included DM2 (fasting blood glucose <7mmol/l), manifest cardiovascular 
disease, use of statins at baseline, use of steroids or non-steroidal anti-infl ammatory drugs at 
baseline, heart failure (NYSE class I or higher), QTc time interval of 450ms or longer on baseline 
ECG, primary dyslipidemias, hypoglycaemia, presence of potential hepatic disease (i.e. subjects 
with ALT, total bilirubin, or alkaline phosphatase levels exceeding 2.5 times the upper limit of 
the normal laboratory values), risk of non compliance, alcohol abuse (>30 units/week) and MRI 
contraindications.
The study consisted of two periods: the screening phase and a double-blind study period with 
a scheduled duration of 52 weeks. After the screening phase eligible patients were randomly 
assigned in a 1:1 ratio to receive either daily therapy with 8mg of rosiglitazone or placebo. The 
treatment was titrated. During the fi rst eight weeks of the study, the participants were treated 
with one tablet daily (rosiglitazone 4mg or placebo). When tolerated, the dosis was doubled 
after 8 weeks. Randomization was based on computer generated codes. The participants were 
stratifi ed for smoking and family history of premature cardiovascular disease. The allocation 
sequence was generated and kept by the institutional trial pharmacist. All subjects received 
intensive lifestyle treatment in addition to rosiglitazone or placebo. Subjects were advised 
to start on a 1500kCal diet and refrain from smoking. In addition they were encouraged to 
increase their level of daily physical activity aiming at an extra energy-expenditure of 270kCal 
per day (i.e. a normal-pace walk of 30 minutes, three times daily). 
All subjects were seen at follow-up visits scheduled at 8, 22, 36 and 52 weeks after randomisa-
tion, thus at least 5 times, by the study physician and the vascular nurse. Emerging hyperten-
sion and diabetes was treated using predefi ned protocols. Hypertension was treated with salt 
restriction and step-up pharmacological therapy starting with hydrochlorothiazide 12,5mg 
followed by treatment with ACE inhibition. Diabetes did not emerge but would have been 
treated with metformin.  
Magnetic Resonance Imaging Protocols 
Carotid artery imaging
Magnetic resonance imaging was performed on a 3Tesla scanner (Philips, Achieva, Best, The 
Netherlands) using a standard Philips SENSE-fl ex-M surface coil as previously described.17 In 
brief, the left carotid artery was examined in all subjects. After localization of the vessel using 
fast gradient echo sequence surveys, a total of ten contiguous transverse slices were acquired 
from the carotid bifurcation covering 2 cm of the carotid bulb and the common carotid artery 
from the fl ow-divider in the proximal (caudal) direction (Figure 1). A dual inversion recovery 
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(black-blood), spoiled segmented k-space fast gradient echo sequence with spectral selective 
fat suppression was used for image acquisition using the following parameters: echo time 3.6 
ms, repetition time (TR) 12 ms, pulse angle 45 degrees, and 2 signal averages were performed. A 
reinversion slice thickness of 3 mm was used. The fi eld of view was 140 mm. With a matrix size of 
306, a voxel size of 0.46mm x 0.46mm x 2mm was obtained. Each MR study took approximately 
30 minutes depending on the cardiac frequency. All images were analysed, using VesselMASS 
software package allowing for a semi-automated quantifi cation of various descriptive param-
eters of the vessel. 
Adipose tissue imaging
Adipose tissue imaging was performed as previously described.18 Subjects were positioned in a 
supine position. The body coil was used for obtaining the images. A sagittal single shot gradient 
echo sequence survey scan was used for the imaging of the vertebral column in the lumbar 
region. Subsequently, a second single shot gradient echo sequence in the transversal plane 
was used for obtaining three contiguous slices of 10mm without angulations. The slices were 
centred at the intervertebral disk level between the 4th and 5th lumbar vertebra. The following 
parameters were used for image acquisition:  echo time 3.7 ms (TE), repetition time 7.5 (TR), 
pulse angle 45 degrees, and 2 signal averages were performed. The images were obtained with 
3 breath holds of 6 seconds. The fi eld of view was 500mm. A voxel size of 1mm x 1.3mm x 
10mm was obtained. Subcutaneous (SAT) and visceral adipose tissue (VAT) areas were quanti-
fi ed using  MASS software package. 
Study outcomes
The predefi ned primary outcome was the change from baseline in MRI assessed total vessel 
wall area of the carotid artery defi ned as the sum of cross-sectional areas of the carotid bulb and 
adjacent part of the common carotid artery. The anatomical hallmark used was the most proxi-
mal separation between the internal and external carotid artery which is called “fl ow-divider” 
Figure 1. Contiguous transverse slices acquired by 3T MRI for the assessment of carotid vessel wall 
characteristics. 






in ultrasonographic literature. From this point, total vessel wall area was calculated from ten 
contiguous transverse slices covering 2cm of the carotid bulb and the most distal part of the 
common carotid artery. Secondary outcomes were other MRI measurements of the carotid 
bulb and common carotid artery including the change in maximum vessel wall thickness. In 
addition, diff erences in anthropometric and laboratory measures were assessed. 
Statistical analysis
A total of 53 patients were required in each study group to provide a statistical power of 90% 
to detect a diff erence of 7mm2 in change of total vessel wall area between the two groups 
within 52 weeks, assuming a standard deviation of 11mm2 and a two sided alfa of 0.05. These 
sample size calculations were based on previously published MRI measured vessel wall data.19 
In that study, a 7 mm2(SD 11) decrease from baseline was reported in vessel wall area after 12 
months of treatment. Assuming a correlation of 0.5 between baseline and measurements after 
12 months within individuals, the SD of change would also be 11. To allow for a dropout of 8%, 
the total sample size was calculated to be 116 patients.
Continuous variables are presented as mean values ± standard deviation or as medians and 
interquartile ranges if the assumption of normality was not met. Categorical variables are 
presented as frequencies(percentages). To calculate the diff erence between study groups in 
changes from baseline we used independent samples t tests for continuous variables or Mann-
Whitney U tests when data were not normally distributed. Analyses were two sided, with a 
P value of 0.05 considered to indicate statistical signifi cance. All analyses were performed on 
an intention-to-treat basis. We used last observation carried forward approach for the one 
patient not completing the full follow-up period. Statistical analyses were performed with SPSS 
software, version 16.0. (SPSS, Chicago, Illinois, USA)
RESULTS
Inclusion and treatment
The study was conducted between September 2005 and August 2007. A total of 801 subjects 
with visceral obesity underwent screening. Of these subjects, 116 subjects underwent ran-
domisation, with 58 patients to the rosiglitazone-lifestyle group and 58 patients to the placebo-
lifestyle group (Figure 2). The intention-to-treat population consisted of these patients. Two 
patients did not complete the trial. One subject was lost to follow-up, and one withdrew consent 
during the course of the treatment. The study was prematurely ended in one participant after 
46 weeks due to a planned total hip replacement operation. MRI was performed at 46 weeks 
in this patient. Compliance in the rosiglitazone-lifestyle (95.6%) and placebo-lifestyle (96.6%) 
group was high and did not signifi cantly diff er (P=0.27). Dose reduction of the study medication 
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to 1 tablet daily was necessary in two patients after complaints of dizziness. The mean duration 
of treatment was 53.7 weeks for rosiglitazone-lifestyle vs. 53.2 weeks for the placebo-lifestyle 
group(P=0.2). Demographic and clinical characteristics of the patients are listed in table 1. No 
statistically signifi cant diff erences were observed between the groups regarding age, waist 
circumference, systolic and diastolic blood pressure, and laboratory values. Non of the patients 
received statins. The classes of anti-hypertensive medication used did not vary signifi cantly 
between the groups. 
Anthropometry and laboratory results
Table 2 summarizes anthropometry and laboratory values for all patients. After 52 weeks, waist 
circumference decreased from 110[102 to 116.5]cm to 99,5[93.3 to 107]cm in the placebo-life-
style group and from 107.5[101 to 116.5]cm to 99[92.8 to 106.5]cm in the rosiglitazone-lifestyle 
group(P=0.18). The reduction in body weight was signifi cantly higher(P=0.047) in placebo 






treated subjects compared to the rosiglitazone group. Reductions in insulin resistance and 
C-reactive protein levels did not signifi cantly diff er between the groups. Total cholesterol levels 
decreased in placebo treated patients from 5.81±0.94mmol/L to 5.48±0.95mmol/L (P=0.003), 
and increased in rosiglitazone treated patients from 5.72±0.86 to 5.92±0.99mmol/L (P=0.12). 
HDL-cholesterol levels increased signifi cantly more in the rosiglitazone treated group. None of 
the participants developed DM2 during the course of the study.






Age (years) 59.6 ±5.0 58.4 ±5.3 0.38
Family history CVD 14 (24%) 13 (22%) 0.83
Current Smoking 14 (24%) 13 (22%) 0.83
Anthropometry
Bodyweight (kg)* 97.0 [86.2 to 105.4] 97.2 [86.9 to 107.5] 0.66
BMI (kg/m2) 30.5 ±3.7 30.0 ±3.5 0.46
Waist circumference (cm)* 110.0 [102.0 to 116.5] 107.5 [101.0 to 116.5] 0.50
Blood pressure
Systolic (mmHg) 148.7 ±16.9 152.5 ±16.8 0.23
Diastolic (mmHg) 88.7 ±9.2 90.8 ±9.0 0.23
Laboratory values
Cholesterol (mmol/l) 5.81±0.94 5.72±0.86 0.48
HDL (mmol/l)* 1.24 [1.04 to 1.47] 1.29 [1.07 to1.50] 0.61
LDL  (mmol/l) 3.70±0.78 3.56±0.73 0.33
Triglycerides (mmol/l)* 1.79 [1.38 to 2.31] 1.71 [1.12 to 2.32] 0.58
Glucose (mmol/l)* 5.15 [5.00 to 5.70] 5.20 [4.68 to 5.80] 0.30
Insulin (μU/mL)* 11.0 [7.5 to 16.0] 12.0 [7.0 to17.0] 0.81
Insulin resistance* 1.5 [1.1 to 2.1] 1.5 [0.9 to 2.1] 0.82
C-reactive protein(mg/L)* 2.91 [1.87 to 4.20] 2.59 [1.61 to 4.17] 0.38
Medication
Statins (%) 0 (0%) 0 (0%) 1
Β-blocker (%)                10 (17%) 6 (10%) 0.28
Diuretics (%) 3 (5%) 5 (9%) 0.46
ACE-inhibitor (%) 4 (7%) 4 (7%) 1
AT2-anatgonist (%) 5 (9%) 6 (10%) 0.75
Ca-antagonist (%) 5 (9%) 2 (3%) 0.24
Plus-minus data are means±(SD). *: data presented as median (interquartile range)
WCR: Waist circumference
Insulin resistance index as calculated using HOMA-IR
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Magnetic resonance imaging
At baseline, visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT) at the waist 
and the gluteofemoral region were not diff erent between the rosiglitazone-lifestyle and the 
Table 2. Anthropometry, blood pressure and Levels of laboratory measurements after 52 weeks of 






Level at 52 weeks
Anthropometry
Bodyweight (kg)* 87.7 [79.5 to 96.6] 91.1 [81.5 to 100.6] 0.20
BMI (kg/m2) 28.0 ±3.2 28.5 ±3.5 0.43
Waist circumference(cm)* 99.5 [93.3-107.0] 99 [92.8-106.5] 0.98
Blood pressure
Systolic (mmHg) 137.0 ±14.5 135.7 ±12.2 0.61
Diastolic (mmHg) 79.5 ±6.5 79.3 ±7.0 0.89
Laboratory values
Cholesterol (mmol/l) 5.48 ±0.95 5.92 ±0.99 0.017
HDL (mmol/l)* 1.29 [1.09-1.52] 1.44 [1.21-1.65] 0.12
LDL  (mmol/l) 3.58 ±0.82 3.73 ±0.87 0.36
Triglycerides (mmol/l)* 1.18 [0.86 to 2.04) 1.21 [0.79 to 1.81] 0.60
Glucose (mmol/l)* 4.85 [4.50 to 5.30] 4.8 [4.4 to 5.2] 0.45
Insulin (μU/mL)* 6.50 [4.00 to 10.75] 6.00 [3.00 to 8.00] 0.20
Insulin resistance* 0.80 [0.50 to 1.30] 0.70 [0.40 to 1.10] 0.35
C-reactive protein(mg/L)* 2.29 [1.55 to 3.99] 1.10 [0.65 to 2.55] 0.003
Change from baseline
Anthropometry
Body weight (kg)* -7.1 [-10.6 to -3.1] -5.3 [-8.2 to -1.2] 0.047
BMI (kg/m2) -2.5 ±2.0 -1.6 ±1.5 0.009
Waist circumference (cm)* -8.8 [-13.0 to -5.0] -7.5 [-11.0 to -3.9] 0.18
Blood pressure
Systolic (mmHg) -11.91 ±14.05 -16.81 ±15.62 0.08
Diastolic (mmHg) -9.26 ±7.81 -11.43 ±9.16 0.17
Laboratory values
Cholesterol (mmol/l) -0.34 ±0.82 0.20 ±0.92 0.002
HDL (mmol/l)* 0.06 [-0.06 to 0.15] 0.13 [0.03 to 0.26] 0.02
LDL  (mmol/l) -0.07 ±1.05 0.17 ±0.92 0.20
Triglycerides (mmol/l)* -0.64 [-0.93 to -0.04] -0.38 [-0.85 to -0.01] 0.50
Glucose (mmol/l)* -0.45 [0.95 to 0.0] -0.40 [-0.85 to 0.0] 0.80
Insulin (μU/mL)* -4.0 [-8.8 to -1.0] -6.0 [-9.5 to -1.5] 0.15
Insulin resistance* -0.70 [-0.60 to -0.20] -0.8 [-1.4 to -0.2] 0.58
C-reactive protein(mg/L)* -0.53 [-1.95 to 0.61] -0.87 [-2.23 to -0.26] 0.22
Plus-minus data are means±(SD). * data presented as median (interquartile range). Insulin resistance index 






placebo-lifestyle group. Median(IQR) VAT signifi cantly decreased in the rosiglitazone-lifestyle 
treated patients from 460.5[348.9 to 602.1]cm² to 329.3[263.1 to 499.7]cm², and from 478.8[375 
to 617.9]cm² to 346.5[283.1 to 445.4]cm² in the placebo-lifestyle group(P<0.001). The diff er-
ence between the groups was not statistically signifi cant(P=0.37).  Waist SAT and gluteofemoral 
SAT decreased with -15.2[-91.5 to 31.7]cm² and -35.2[-100.3 to 22.35]cm² in the rosiglitazone-
lifestyle group and with -82.8[-158.8 to -33.1]cm² and -84[-160.8 to -36.9]cm² in the placebo-
lifestyle group. The change in waist SAT and gluteofemoral SAT after 52 weeks was signifi cantly 
diff erent between the groups(P<0.001). 
Table 3. Measures of Magnetic Resonance imaging of the Carotid Artery
Variable Placebo-lifestyle Rosiglitazone-lifestyle P-Value
At baseline
No. of patients 58 58
Vessel wall area ( cm²)
Total 4.56 [4.16 to 5.09] 4.52 [3.80 to 5.34] 0.85
Common carotid artery 1.82 [1.52 to 2.05] 1.69 [1.46 to 1.98] 0.28
Carotid Bulb 2.74 [2.35 to 3.09] 2.82 [2.34 to 3.26] 0.58
Maximal vessel wall thickness (mm)
Common carotid artery 1.64 [1.46 to 1.83] 1.48 [1.36 to 1.75] 0.03
Carotid Bulb 2.06 [1.82 to 2.47] 2.09 [1.86 to 2.57] 0.88
At 52 weeks
No. of patients 56 58
Vessel wall area ( cm²)
Total 4.53 [3.99 to 5.15] 4.63 [3.99 to 5.31] 0.39
Common carotid artery 1.78 [1.51 to 1.99] 1.69 [1.46 to 2.09] 0.85
Carotid Bulb 2.73 [2.39 to 3.01] 2.87 [2.40 to 3.35] 0.20
Maximal vessel wall thickness (mm)
Common carotid artery 1.59 [1.48 to 1.75] 1.57 [1.44 to 1.73] 0.53
Carotid Bulb 2.09 [1.88 to 2.31] 2.11 [1.91 to 2.42] 0.61
Diff erence from baseline at 52 weeks
Vessel wall area ( cm²)
Total 0.001 [-0.25 to 0.20] 0.040 [-0.24 to 0.38] 0.19
Common carotid artery -0.002 [-0.12 to 0.07] 0.035 [-0.06 to  0.15] 0.17
Carotid Bulb -0.039 [-0.21 to 0.14) 0.040 [-0.17 to 0.19] 0.18
Maximal vessel wall thickness (mm)
Common carotid artery -0.009 [-0.08 to 0.10] 0.071 [-0.06 to 0.16]* 0.16
Carotid Bulb -0.005 [-0.20 to 0.18] 0.036 [-0.16 to 0.17] 0.53
Data presented as median (interquartile range).
*: Signifi cant increase within the group after one year treatment (p<0.05).
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Table 3 summarizes the results of measurements of the magnetic resonance imaging of the 
carotid artery. Baseline measures of carotid atherosclerosis were not diff erent between the 
groups, except for a higher maximum vessel wall thickness in the common carotid artery in the 
placebo group (P=0.03).
Primary Outcome Measure. The primary outcome, the change from baseline of the 
median(IQR) change in carotid-artery total vessel wall area was 0.04[-0.24 to 0.38]cm² in the 
rosiglitazone-lifestyle group and 0.001[-0.25 to 0.20]cm² in the placebo-lifestyle group. The 
diff erence did not reach statistical signifi cance (P=0.19).
Secondary Outcome Measure. The median(IQR) maximum vessel wall thickness of the 
common carotid artery signifi cantly increased by 0.071[-0.06 to 0.16]mm in the rosiglitazone-
lifestyle group from 1.48[1.36-1.75]mm to 1.57[1.44-1.73]mm (P=0.04). Maximum vessel wall 
thickness of the common carotid artery non-signifi cantly decreased -0.009[-0.08 to 0.10]mm in 
the placebo-lifestyle group from 1.64[1.46-1.83]mm at baseline to 1.59[1.48-1.75]mm (P=0.6). 
The diff erence between the groups did not reach statistical signifi cance (P=0.16). For all other 
measures of carotid atherosclerosis, including common carotid artery vessel wall area and 
maximal vessel wall thickness, and carotid bulb vessel wall area no diff erences were observed 
between rosiglitazone-lifestyle and placebo-lifestyle treated patients. 
Clinical adverse events
No cardiovascular events or interventions occurred during the treatment period. There were 4 
hospital admissions in each of the groups, none of which under acute circumstances. There were 
9 cases of new or increased oedema in the placebo group compared to 12 in the rosiglitazone 
group (p=0.45). Two patients were registered with complaints of dizziness in the rosiglitazone 
group compared to none in the placebo. In 3 patients of the placebo group ECG changes were 
seen at the end of study visit compared to none in the rosiglitazone group. Exercise testing was 
normal in all three patients. Six cases of infections were registered in the placebo group during 
the treatment period compared to 2 in the rosiglitazone group. There were 2 other registered 
clinical adverse events in the placebo group compared to 6 in the rosiglitazone treated patients. 
DISCUSSION
The results of our study showed that the addition of rosiglitazone to intensive lifestyle therapy 
did not prevent the progression of atherosclerosis in non-diabetic patients with visceral obe-
sity and elevated C-reactive protein levels. The primary outcome, the change in carotid artery 
median total vessel wall area, did not signifi cantly diff er between the two study groups, nor did 






There are at least three possible explanations for the absence of an additional eff ect on MRI 
measured carotid-artery vessel wall measures in patients receiving rosiglitazone: a lack of vas-
cular benefi t conferred by rosiglitazone, the potential benefi cial eff ects of lifestyle therapy on 
the vascular wall concealing a possible eff ect of rosiglitazone, and the inability of the measure-
ment technique to accurately refl ect changes in atherosclerotic burden.
The fi rst explanation to consider is that the pharmacological eff ects of rosiglitazone, includ-
ing improved insulin resistance and lowering of elevated CRP levels, is ineff ective for slowing 
atherosclerosis in non-diabetic patients with visceral obesity and elevated CRP. This is in line 
with the observation published, while our study was ongoing, that rosiglitazone treatment 
did not reduce carotid-artery intima media thickness progression in insulin resistant patients 
without DM2.14 Although this population predominantly consisted of females, the baseline 
characteristics were very similar to that of our study population. This study together with our 
now reported data are in sharp contrast to previously published data in patients with DM2. 
Rosiglitazone and other PPAR-γ agonists signifi cantly reduced carotid-artery intima media 
thickness progression in patients with DM2.14, 20-23 . Pioglitazone, a partial PPAR gamma agonist 
was also recently shown to lower the rate of progression of coronary atherosclerosis compared 
with glimepiride in diabetic patients.24 
However, comparing the results of our study with previous studies in insulin resistant and 
diabetic patients is complicated by the fact that we assigned lifestyle therapy to all patients. 
Intensive lifestyle therapy is the fi rst recommended step in the treatment of patients with the 
metabolic syndrome. We argued it mandatory to assess the eff ect of rosiglitazone in addition 
to measures improving lifestyle. Thus, all patients were instructed to increase their level of daily 
exercise. In addition, all patients were advised to restrict their dietary caloric intake. Frequent 
counselling by a vascular nurse trained in lifestyle therapy was used to reinforce the measures 
taken in every patient. The lifestyle intervention was successful as measured by anthropometric 
and laboratory values. Bodyweight and waist circumference decreased with 7.1kg and 8.8cm 
respectively in placebo-lifestyle treated patients. Blood pressure improved by 11.9/9.3mmHg. 
In addition, insulin resistance and CRP levels improved. The benefi cial eff ects of lifestyle were 
underlined by the MRI measurements of visceral and subcutaneous adipose tissue depots. In 
comparison with rosiglitazone-lifestyle treated patients, placebo-lifestyle treated patients lost 
more subcutaneous adipose fat. Intriguingly, the primary endpoint, which was the change 
in carotid-artery median vessel wall area, increased only by 0.001cm2 in the placebo-lifestyle 
treated patients.  Of the secondary endpoints, maximal vessel wall thickness did not change. 
Thus, it seemed that intensive lifestyle therapy resulted in remarkable cardiometabolic improve-
ments that associate with stable measures of carotid-artery vessel wall characteristics during 
the 52 weeks follow-up. These observations suggest that intensive lifestyle treatment may 
prevent the progression of atherosclerosis in visceral obese patients with elevated CRP levels. 
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Nevertheless, the observations now reported may be the result of the inability of MR black 
blood carotid-artery vessel wall imaging to show diff erences within a 52 weeks follow-up 
period. This argument should receive serious attention as MRI as an intermediate endpoint to 
assess changes in atherosclerotic burden is not as established as for instance carotid-artery 
intima media thickness measurements by ultrasonography. Although MRI is known to refl ect 
histologic diff erences in the carotid-artery, and we powered our study on previous published 
reports19, and we published the reproducibility of our test characteristics17, we cannot deny 
this is the fi rst study using this technique in the setting of a randomised controlled trial for 
assessing atherosclerotic burden in visceral obese men with elevated CRP levels. 
The present observations are of interest in the context of the ongoing debate regarding the car-
diovascular safety of rosiglitazone treatment, particularly as little is known on the infl uence of 
rosiglitazone on early atherosclerosis. Recent meta-analyses related rosiglitazone treatment to 
an increased risk of myocardial infarction and possible cardiovascular mortality.25, 26 An interim 
analysis of the RECORD study, however, showed no evidence of any increase in death from car-
diovascular causes in association with rosiglitazone treatment.27 Such discrepancies have also 
been reported with regard to the eff ects of rosiglitazone on the progression of atherosclerosis, 
suggesting varying eff ects in diff erent populations. In line with these observations, European 
health authorities (EMEA) have recommended additional caution in prescribing rosiglitazone in 
patients with ischemic heart disease and peripheral artery disease.   
In conclusion, our study showed that the addition of rosiglitazone to lifestyle therapy did not 
prevent the progression of atherosclerosis in non-diabetic patients with visceral obesity and 
elevated C-reactive protein levels. Of the possible explanations discussed a lack of vascular 
benefi t conferred by rosiglitazone when given in addition to the benefi cial eff ects of lifestyle 
therapy could be a valid point. Although the 3T MRI measurement technique needs further 
validation as a surrogate measure for atherosclerotic burden its potential remains high after 
this study that raised data useful for the calculation of the statistical power for future trials. 
Finally, this study underlines the impressive impact of lifestyle therapy on many clinical features 
in male visceral obese patients with elevated CRP levels. 
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Patients with visceral obesity and elevated C-reactive protein (CRP) levels are regarded at 
increased cardiovascular risk even in the absence of type 2 Diabetes Mellitus (DM2). Circulat-
ing endothelial progenitor cells are thought to refl ect cardiovascular risk and their counts are 
reduced in association with infl ammation and cardiovascular risk factors. Since rosiglitazone 
has anti-infl ammatory potential, we hypothesized it would improve circulating progenitor cell 
profi les in men with visceral obesity (VO) and elevated C-reactive protein levels when given in 
addition to intensive lifestyle treatment.
Methods
We conducted a double blind, placebo controlled, randomized 52 weeks trial comparing the 
eff ects of daily therapy with 8 mg rosiglitazone plus intensive lifestyle therapy or placebo plus 
intensive lifestyle therapy  in 45 non-diabetic men with visceral obesity and CRP levels of 1.8 
mg/L or higher. The primary outcome measures were the diff erence between the groups in 
CD34+ and CD34+KDR+ cells as quantifi ed by fl uorescence-activated cell sorter analysis after 
appropriate staining and gating. MRI was used to assess adipose tissue distribution.
Results
The fi rst outcome measure, the median change[interquartile range (IQR)] from baseline in 
CD34+ cells, was 0.654[0.033 to 1.083]/μL in the rosiglitazone-lifestyle group and 0.142[-0.470 
to 0.426]/μL in placebo-lifestyle group. The diff erence between the groups was statistically 
signifi cant (P=0.03). For CD34+KDR+ cells, the median (IQR) change was 0.001[-0.024 to 0.020]/
μL in the rosiglitazone-lifestyle group and -0.002 [-0.025 to 0.017]/μL in placebo-lifestyle group 
(p=0.62). Rosiglitazone-lifestyle and placebo-lifestyle reduced median [IQR] waist circumfer-
ence by -9.0[-15.0 to -4.0]cm and -10.5[-15.5 to -5.0]cm and median [IQR] CRP levels by -1.12[-
2.22 to -0.16] and -0.19[-1.52 to 1.91]mg/L, respectively. MRI assessment of fat stores revealed 
signifi cant higher decreases in waist and hip subcutaneous fat stores in placebo-lifestyle 
treated patients. 
Conclusions
Rosiglitazone signifi cantly increased circulating CD34+ cell counts when given on top of 
intensive lifestyle therapy in men with visceral obesity and elevated C-reactive protein levels 
compared to placebo. No eff ect of rosiglitazone was observed for CD34+KDR+ cells. 
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INTRODUCTION
Endothelial progenitor cells (EPC) are thought to refl ect vascular damage.1-4 They are shown 
to improve endothelial function, promote vascular repair, and to induce neovascularization.5-7 
Signifi cantly lower numbers of EPCs were reported in patients with insulin resistance and the 
metabolic syndrome (MS).8, 9 Lower EPC numbers and impaired functional activity have been 
shown in patients with type 2 diabetes mellitus (DM2).2, 10, 11 Furthermore, cell counts were 
found to be decreased in chronic infl ammatory diseases such as rheumatoid arthritis.12 Taken 
together, circulating endothelial progenitor cells are interesting potential intermediate cardio-
vascular endpoints. They are related to metabolic derangements such as insulin resistance, and 
systemic infl ammation13, 14 on the one hand, but also refl ect vascular damage on the other.1-4 
Visceral obesity (VO) and elevated C-reactive protein levels, are independent risk factors for 
myocardial infarction15 and cardiovascular mortality.16, 17 The fi rst step in the treatment of 
subjects with visceral obesity is lifestyle therapy. Although lifestyle interventions are known 
to result in signifi cant improvements in progenitor cell profi les18-20, these eff ects have not 
been studied in non-diabetic visceral obese patients with elevated CRP levels. In addition to 
intensive lifestyle therapy, medication that alters fat distribution, increases insulin sensitivity 
and decrease systemic infl ammation may have additive potential in improving progenitor cell 
profi les. Rosiglitazone is a peroxisome-proliferator-activated receptor γ (PPARγ) agonist that 
alters fat distribution and modulates metabolic and infl ammatory gene repertoires.21 More 
specifi cally, it increases insulin sensitivity, redistributes fat from visceral to peripheral stores 
and decreases CRP levels.22, 23 Given these characteristics, we hypothesized that rosiglitazone 
would improve progenitor cell profi les in men with visceral obesity and elevated C-reactive 
protein levels, when given in addition to intensive lifestyle therapy. 
In this study, we sought to determine whether the daily administration of 8 mg of rosiglitazone 
in combination with intensive lifestyle therapy would improve CD34+ and CD34+KDR+ cell 
counts in non-diabetic patients with visceral obesity and elevated CRP levels. We assessed 
these cells in a predefi ned sub-study of our study called “A 52 week double-blind randomized 
controlled trial comparing the eff ect of Rosiglitazone versUs placeBo on the prevENtion of 
progression of atheroSclerosis in high risk patients without diabetes (RUBENS) trial”. 
MATERIALS AND METHODS
Study design
This prospective randomized double-blind placebo controlled trial was performed at LUMC, 






The study was approved by the institutional review committee and conducted according to 
the principles expressed in the Declaration of Helsinki. Men of 50 years or older were eligible to 
participate in the study if  a waist circumference ≥94 cm and a CRP levels of 1.8 mg/L or higher 
was present. The cut-off  value of 1.8mg/L for CRP was chosen based on the previously reported 
median of CRP in males in a large epidemiological study.24 Additional inclusion criteria were 
the presence of either at least two other metabolic syndrome criteria according to the IDF 
defi nition.25 Exclusion criteria included DM2 (fasting blood glucose ³7mmol/l), manifest cardio-
vascular disease, smoking, presence of premature cardiovascular disease in a fi rst degree family 
member, use of statins at baseline, use of steroids or non-steroidal anti-infl ammatory drugs at 
baseline, heart failure (NYSE class I or higher), QTc time interval of 450ms or longer on baseline 
ECG, primary dyslipidemias, hypoglycaemia, presence of potential hepatic disease (i.e. subjects 
with ALT, total bilirubin, or alkaline phosphatase levels exceeding 2.5 times the upper limit of 
the normal laboratory values), risk of non compliance, alcohol abuse (>30 units/week) and MRI 
contraindications. The study consisted of two periods: the screening phase and a double-blind 
study period with a scheduled duration of 52 weeks. After the screening phase eligible patients 
were randomly assigned in a 1:1 ratio to receive either daily therapy with 8 mg of rosiglitazone 
or placebo. The treatment was titrated. During the fi rst eight weeks of the study, the partici-
pants were treated with one tablet daily (rosiglitazone 4mg or placebo). When tolerated, the 
dosis was doubled after 8 weeks. Randomization was based on computer generated codes. The 
allocation sequence was generated and kept by the institutional trial pharmacist. All subjects 
received intensive lifestyle treatment in addition to rosiglitazone or placebo. Subjects were 
advised to start on a 1500 kCal diet and refrain from smoking. In addition they were encour-
aged to increase their level of daily physical activity aiming at an extra energy-expenditure of 
270 kCal per day (i.e. a normal-pace walk of 30 minutes, three times daily). All subjects were 
seen at follow-up visits scheduled at 8, 22, 36 and 52 weeks after randomisation, thus at least 5 
times, by the study physician and the vascular nurse. Emerging hypertension and diabetes was 
treated using predefi ned protocols. Hypertension was treated with salt restriction and step-up 
pharmacological therapy starting with hydrochlorothiazide 12,5mg followed by treatment 
with ACE inhibition. Diabetes did not emerge but would have been treated with metformin.  
CD34+ and CD34+KDR+ cells
Enumeration of circulating CD34+ and CD34+KDR+ cells was performed as recently described.18 
This method uses Trucount tubes that contain a defi ned number of brightly fl uorescent 
microbeads, permitting the acquisition of absolute counts of cells, even at very low numbers. 
Circulating CD34+ cells were defi ned as cells with low-expression of CD45, positive for CD34, 
and located in the lympho-gate on a side- and forward-scatter plot. This gating strategy was 
extended by calculating the number of CD34+ cells that also expressed vascular endothelial 
growth factor receptor-2 (VEGFR-2) to defi ne the number of CD34+KDR+ cells. This strategy 
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avoids inclusion of mature endothelial cells, which are also positive for CD34 and VEGFR-2, 
since they are located outside the lympho-gate.
MRI adipose tissue imaging
Magnetic resonance imaging was performed on a 3T scanner (Philips, Achieva, Best, The Neth-
erlands) using the body coil as previously reported.26 In short: After performing the preparatory 
scans, a single shot gradient echo sequence in the transversal plane was used for obtaining 
three contiguous slices of 10mm without angulations centered at the intervertebral disk level 
between the 4th and 5th lumbar vertebra. Images were assessed using the MASS software pack-
age allowing quantifi cation of visceral adipose tissue (VAT) and subcutaneous adipose tissue 
(SAT).
Study outcomes
The predefi ned primary outcome was the change from baseline in the number of CD34+ and 
CD34+KDR+ cells after 52 weeks of treatment with either rosiglitazone or placebo in addition 
to intensive lifestyle treatment. Furthermore, diff erences in anthropometric and laboratory 
measures were assessed. 
Statistical analysis
Continuous variables are presented as mean values ± standard deviation or as medians and 
interquartile ranges if the assumption of normality was not met. Categorical variables are pre-
sented as frequencies (percentages). To calculate diff erence between study groups in changes 
from baseline we used independent samples t tests for continuous variables or Mann-Whitney 
U tests when data were not normally distributed. Comparisons within the groups were per-
formed with paired samples t tests or Wilcoxon tests for related samples depending on the 
distribution. All analyses are two sided, with a P value of 0.05 considered to indicate statisti-




The study was conducted between September 2005 and August 2007. A total 45 subjects under-
went randomization, with 23 patients to the rosiglitazone-lifestyle group and 22 patients to the 
placebo-lifestyle group.  All subjects completed the study. Compliance in the rosiglitazone-
lifestyle (96.8%) and placebo-lifestyle (97.7%) group was high and did not diff er (p=0.49). 
Demographic and clinical characteristics of the patients are listed in table 1. No statistically 






systolic and diastolic blood pressure, and laboratory values. None of the patients received 
statins. The classes of anti-hypertensive medication used did not vary signifi cantly between the 
groups. None of the participants developed DM2 during the course of the study.
Anthropometry and laboratory results
Table 2 summarizes anthropometry and laboratory values for all patients including changes 
of the values from baseline. After 52 weeks, waist circumference decreased from 108[101 to 
113]cm to 97[92 to 103]cm in the rosiglitazone-lifestyle group and from 109[102 to 116.5]cm 
to 98[93 to 107.3]cm in the placebo-lifestyle group(P=0.48). Both systolic and diastolic blood 
pressures were signifi cantly reduced in within both groups during follow-up (P≤0.001). For the 
diff erence between groups in systolic blood pressure, a trend toward statistical signifi cance was 
seen (P=0.06), while the diff erence in diastolic blood pressure was not statistically signifi cant 
(P=0.15). LDL-cholesterol levels increased from 3.69±0.70 mmol/L to 4.11±0.79mmol/L in rosi-
glitazone-lifestyle treated patients and decreased from 3.83±0.72mmol/L to 3.56±0.82mmol/L 






Age (years) 58.7 (4.9) 59.9 (5.1) 0.43
Anthropometry
Bodyweight (kg) 93.1 (86.1 to 102.5) 96.0 (87.8 to 104.0) 0.92
BMI (kg/m2) 29.9 [28.4 to 32.5] 29.0 [27.4 to 30.8] 0.17
Waist circumference (cm) 109.0 (102.0 to 116.5) 108.0 (101.0 to 113.0) 0.55
Blood pressure
Systolic (mmHg) 148.3 (15.7) 153.7 (17.3) 0.28
Diastolic (mmHg) 87.6 (7.6) 89.8 (8.4) 0.36
Laboratory values
Cholesterol (mmol/l) 5.85 (0.92) 5.89 (0.84) 0.889
HDL (mmol/l) 1.28 (0.30) 1.34 (0.25) 0.477
LDL  (mmol/l) 3.83 (0.72) 3.69 (0.70) 0.518
Triglycerides (mmol/l) 1.61 (1.11 to 2.00) 1.74 (1.38 to 2.19) 0.301
Glucose (mmol/l) 5.10 (4.90 to 5.83) 5.0 (4.7 to 5.5) 0.245
Insulin (μU/mL) 9.63 (6.00 to 15.25) 9.0 (4.0 to 14.0) 0.509
Insulin resistance 1.40 (1.15 to 2.23) 1.3 (0.6 to 1.9) 0.152
C-reactive protein (mg/L) 2.57 (1.64 to 3.25) 2.46 (2.10 to 3.38) 0.759
MRI adipose tissue distribution
Waist visceral fat (cm2) 453.1 [367.3 to 628.0] 403.9 [326.1 to 496.7] 0.19
Waist subcutaneous fat (cm2) 750.4 [667.7 to 1105.9] 731.0 [692.4 to 923.9] 0.54
Hip subcutaneous fat (cm2) 592.2 [506.6 to 693.6] 567.1 [512.1 to 707.9] 0.77
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Table 2. Anthropometry, blood pressure and Levels of laboratory measurements after 52 weeks of 





Level at 52 weeks
Anthropometry
Bodyweight (kg) 86.5 (80.5 to 94.3) 90.2 (81.7 to 97.7) 0.42
BMI (kg/m2) 27.7 [25.3 to 29.8] 27.5 [25.0 to 28.3] 0.47
Waist circumference(cm) 98.0 (93.0 to 107.3) 97.0 (92.0 to 103.0) 0.53
Blood pressure
Systolic (mmHg) 138.6 (14.4) 135.9 (13.2) 0.52
Diastolic (mmHg) 78.2 (6.9) 78.0 (7.1) 0.56
Laboratory values
Cholesterol (mmol/l) 5.46 (0.92) 6.24 (0.86) 0.006
HDL (mmol/l) 1.34 (0.30) 1.52 (0.24) 0.03
LDL  (mmol/l) 3.56 (0.82) 4.11 (0.79) 0.03
Triglycerides (mmol/l) 1.14 [0.74 to 1.71] 1.22 [0.94 to 1.70] 0.90
Glucose (mmol/l) 4.70 (4.43 to 5.30) 4.80 (4.35 to 5.15) 0.95
Insulin (μU/mL) 4.50 (3.00 to 8.00) 4.50 (3.00 to 7.00) 0.50
Insulin resistance 0.55 (0.40 to 1.00) 0.50 (0.40 to 0.80) 0.44
C-reactive protein(mg/L) 2.42 (0.84 to 4.70) 1.05 (0.59 to 2.08) 0.04
MRI adipose tissue distribution
Waist visceral fat (cm2) 313.6 (268.8 to 367.7) 315.40 (228.6 to 372.4) 0.79
Waist subcutaneous fat (cm2) 684.1 (580.7 to 887.3) 696.5 (593.0 to 876.0) 0.98
Hip subcutaneous fat (cm2) 500.5[372.1 to 558.2] 521.4[393.6 to 598.4] 0.47
Change from baseline
Anthropometry
Body weight (kg) -8.6 [-13.5 to -2.9] -6.7 [-8.8 to -0.9] 0.06
BMI (kg/m2) -2.7 [-4.4 to -1.0] -1.9 [-2.5 to -0.3] 0.08
Waist circumference (cm) -10.5 [-15.5 to -5.0] -9.0 [-15.0 to -4.0] 0.48
Blood pressure
Systolic (mmHg) -9.8 (12.2) -17.9 (15.9) 0.06
Diastolic (mmHg) -8.4 (7.1) -11.9 (8.7) 0.15
Laboratory values
Cholesterol (mmol/l) -0.39 (0.65) 0.39 (0.96) 0.003
HDL (mmol/l) 0.05 (0.23) 0.18 (0.15) 0.04
LDL  (mmol/l) -0.27 (0.61) 0.42 (0.86) 0.003
Triglycerides (mmol/l) -0.32 [-0.81 to 0.06] -0.44 [-0.85 to -0.22] 0.49
Glucose (mmol/l) -0.5 [-1.0 to -0.1] -0.4 [-0.8 to 0.1] 0.54
Insulin (μU/mL) -4.5 (-7.3 to -1.8) -4.5 (-8.3 to 0.0) 0.96
Insulin resistance -0.8 (-1.2 to -0.3) -0.7 (-1.1 to -0.2) 0.59
C-reactive protein(mg/L) -0.19 (-1.52 to 1.91) -1.12 (-2.22 to -0.16) 0.049
MRI adipose tissue distribution
Waist visceral fat (cm2) -147.5 [-256.4 to -50.8] -86.4 [-173.4 to -27.0] 0.06
Waist subcutaneous fat (cm2) -112.0 [-231.9 to -57.5] -55.2 [-99.4 to 15.2] 0.006






in placebo-lifestyle treated patients. The diff erence between the groups was statistically signifi -
cant (P=0.003). HDL-cholesterol levels increased from 1.34±0.25mmol/L to 1.52±0.24mmol/L 
in rosiglitazone treated patients and from 1.28±0.30mmol/L to 1.34±0.30mmol/L in the 
placebo-lifestyle group. The diff erence between groups was statistically signifi cant (P=0.04). 
Median[IQR] CRP levels decreased in the rosiglitazone-lifestyle group from 2.46[2.10 to 3.38]
mg/L to 1.05[0.59 to 2.08]mg/L and from 2.57[1.64 to 3.25]mg/L to 2.42[0.84 to 4.70]mg/L in 
placebo-lifestyle treated patients. The change in CRP levels of -1.12 [-2.22 to -0.16]mg/L in rosi-
glitazone treated patients compared to -0.19 [-1.52 to 1.91] mg/L in the placebo group reached 
borderline statistical signifi cance (P=0.049).
CD34+ and CD34+KDR+ cell counts
Table 3 summarizes the results of the cellular endpoints of the study. The cell counts of CD34+ 
and CD34+KDR+ are given at baseline, after 52 weeks of treatment and the median change 
from baseline is shown. Rosiglitazone-lifestyle treatment resulted in an increase of median[IQR] 
CD34+ of 0.654 [0.033 to 1.083]/μL. In placebo-lifestyle treated patients an increase of 0.142 
[-0.47 to 0.426]/μL was observed. The diff erence in CD34+ between the groups was statistically 
signifi cant(p=0.03). The change in median[IQR] CD34+KDR+ counts were 0.001[-0.024 to 0.020]/
μL in rosiglitazone-lifestyle treated patients and -0.002[-0.025 to 0.017]/μL in placebo treated 
patients. This change in CD34+KDR+ between groups did not reach statistical signifi cance.
MRI adipose tissue distribution
Visceral fat, waist subcutaneous fat and hip subcutaneous fat were very similar at baseline 
(Table 1). After 52 weeks of treatment, the visceral and subcutaneous adipose tissue did not 




No. of patients 22 23
CD34+KDR+ (number/μL) 0.028 [0.013 to 0.043] 0.013 [0 to 0.032] 0.07
CD34+ (number/μL) 1.181 [0.786 to 2.160] 1.311 [0.476 to 1.845] 0.65
At 52 weeks
No. of patients 22 23
CD34+KDR+ (number/μL) 0.016 [0 to 0.057] 0.016 [0 to 0.043] 0.81
CD34+ (number/μL) 1.475 [0.737 to 2.103] 1.580 [1.052 to 2.707] 0.28
Diff erence from baseline at 52 weeks
CD34+KDR+ (number/μL) -0.002 [-0.025 to 0.017] 0.001 [-0.024 to 0.020] 0.62
CD34+ (number/μL) 0.142 [-0.470 to 0.426] 0.654 [0.033 to 1.083]* 0.03
*: Signifi cant increase within the group after one year treatment (p<0.01).
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signifi cantly diff er between groups (Table 2). However, the median [IQR] change of waist 
subcutaneous adipose tissue had decreased signifi cantly more in the placebo-lifestyle group 
by -112[-231.9 to -57.5]cm² compared to -55.2 [-99.4 to 15.2]cm² in the rosiglitazone-lifestyle 
group (P=0.006). Visceral adipose tissue decreased with -147.5 [-256.4 to -50.8]cm² in the 
placebo-lifestyle group and with -86.4 [-173.4 to -27.0]cm² in the rosiglitazone-lifestyle group 
(P=0.06).
DISCUSSION
The results of our study demonstrate that the addition of rosiglitazone therapy to intensive 
lifestyle treatment signifi cantly changed circulating progenitor cell profi les in non-diabetic 
patients with visceral obesity and elevated C-reactive protein levels. The primary outcome, the 
change in the number of CD34+ cells after 52 weeks of treatment was signifi cantly increased 
in rosiglitazone-lifestyle treated patients. The other outcome parameter, the change in CD34+/
KDR+ cell counts, did not signifi cantly diff er between the groups. 
Endothelial progenitor cells are known to correlate with cardiovascular risk factors1, 2 and have 
been proposed as surrogate biological markers of vascular function and cardiovascular dis-
ease.7  In this regard, CD34+ cells are most closely related to cardiovascular risk.8 We observed 
signifi cant increases in CD34+, but not in CD34+/KDR+ cells in response to rosiglitazone 
therapy in visceral obese male patients with elevated C-reactive protein levels. The available 
data on the in vivo eff ects of rosiglitazone on circulating endothelial progenitor cell counts are 
very limited. In a small, uncontrolled clinical study, 12 weeks of rosiglitazone treatment did not 
change CD34+ cell counts in recent onset DM2 patients.27 In an experimental mouse model, 
rosiglitazone treatment was shown to promote the diff erentiation of bone marrow derived 
progenitor cells toward the endothelial linage after the induction of endothelial damage.28 In 
contrast to the results of our study, treatment with pioglitazone has been shown to increase 
both CD34+/KDR+, and CD34+ cell counts in patients with coronary artery disease and normal 
glucose tolerance and in patients with DM2.29, 30 Pioglitazone treatment was also shown to 
improve migratory response, adhesion capacity and colony formation capacity of endothelial 
progenitor cells.29, 30 These data and the results of our study show that PPARγ agonists could 
increase CD34+ peripheral blood cell counts. The eff ects on CD34+KDR+ cells vary depending 
on the specifi c PPARγ agonist used.  
Several aspects of our study should be addressed when interpreting the results: the study 
population, the concomitant eff ects of lifestyle intervention, and, the duration of the follow-up 
period. First, our study population consisted of non-diabetic male patients with visceral obesity 






response after rosiglitazone treatment has not previously been studied in these patients. In 
this regard, the current results are additive to previous studies showing eff ects in non-diabetic 
patients without manifest cardiovascular disease. Secondly, the eff ect of rosiglitazone was 
assessed in addition to lifestyle therapy in our study. Lifestyle therapy is the fi rst treatment step 
in subjects with visceral obesity. The eff ects of lifestyle therapy are clearly seen in the placebo-
lifestyle arm of our study. Lifestyle intervention resulted in reductions in body weight, waist 
circumference, blood pressure and some metabolic variables. Lifestyle interventions are known 
to signifi cantly improve progenitor cell profi les.18-20  We now found that addition of rosigli-
tazone to eff ective lifestyle therapy further increased CD34+ cell counts. Finally, the presented 
observations of our study concern a follow-up period of 52 weeks while earlier reports of both 
rosiglitazone and pioglitazone concern much shorter follow-up periods. Thus, our study is 
clearly additive as it provides the eff ect of long term follow-up to the earlier reports of studies 
with shorter follow-up periods. 
        
This study has limitations. First, the infl uence of rosiglitazone independent of lifestyle treat-
ment could not be assessed in our study. Furthermore, all patients in our study were males. 
The current observations remain to be confi rmed in female populations. Current smoking and 
the presence of premature familial CVD were exclusion criteria in our study due to their known 
impact on circulating progenitor cells. As a result, the observations of this study can not be 
extrapolated to subjects with those characteristics. Finally, we only determined CD34+ and 
CD34+/KDR+ cell counts and did not characterize the functional properties of these cells which 
may provide valuable additional information in future studies.
In summary, we observed signifi cant increases in CD34+ cell counts in response to rosiglitazone 
therapy in addition to successful intensive lifestyle treatment in non-diabetic men with visceral 
obesity and elevated C-reactive protein levels.
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SUMMARY AND CONCLUSIONS
The aim of this thesis was to explore the relation between visceral obesity and the accompany-
ing metabolic disturbances, systemic infl ammation and the atherosclerotic process. A newly 
developed magnetic resonance vessel wall imaging technique was implemented in phenotyp-
ing patients and as a therapeutic endpoint in a randomised controlled setting. A three step 
approach was chosen for this purpose. First, the magnetic resonance black blood vessel wall 
imaging technique at the magnetic fi eld strength of 3 Tesla was developed and validated. 
Secondly, phenotyping of viscerally obese subjects was performed with special attention for 
the role of systemic infl ammation and atherosclerosis. Finally, in the setting of a randomised 
controlled trial, the impact of reducing visceral obesity and systemic infl ammation with lifestyle 
intervention and rosiglitazone treatment (PPARγ agonist) on the progression of atherosclerosis 
was assessed.
PART I: 3T MAGNETIC RESONANCE BLACK BLOOD VESSEL WALL IMAGING 
Magnetic resonance black-blood vessel wall imaging at the magnetic fi eld strength of 3 Tesla 
was developed to assess the carotid artery vessel wall characteristics. A double inversion 
recovery fast gradient echo sequence was used on a commercial 3T system for the acquisition 
of images of the carotid artery. After development and optimisation of the scanning sequence, 
the reproducibility of the measurements was evaluated in a study using three repeated mea-
surements as described in Chapter 2. A high reproducibility of the measurements was shown 
both for the carotid vessel wall area and the vessel wall thickness. Vessel wall area is a global 
measure for the atherosclerotic disease burden while increased vessel wall thickness refl ects 
focal atherosclerotic changes of the vascular wall. Magnetic resonance vascular imaging was 
shown to be able to assess vessel wall characteristics of the carotid artery with high reproduc-
ibility. 
Three Tesla vascular measurements of the carotid artery showed high dimensional precision 
with ultrasound assessments of the same vascular structure as reference as described in chap-
ter 3. Ultrasound measured intima media thickness of the carotid artery is a frequently used and 
extensively validated imaging modality for the evaluation of carotid atherosclerosis. Signifi cant 
correlations were observed between ultrasound measured intima media thickness and the MRI 
measured vessel wall thickness. Carotid luminal dimensional measurements evaluated by both 
techniques were also shown to be very similar. Furthermore, MRI successfully discriminated 







After establishing the reproducibility of the newly developed magnetic resonance vessel wall 
imaging technique and its ability in discriminating vessel wall characteristics of subjects with 
varying cardiovascular risk profi les, the precision of the measurements were assessed using 
ultrasound as reference. This imaging technique could now be applied in phenotyping patients 
and as a therapeutic endpoint in a randomised controlled setting as described in the following 
chapters. 
PART II: PHENOTYPING OF VISCERAL OBESITY
Both visceral obesity and the accompanying metabolic disturbances are thought to contribute 
to an increased risk of developing future cardiovascular disease. In chapter 4, vessel wall 
characteristics of visceral obese subjects with and without the Metabolic Syndrome were 
evaluated in comparison to patients who recently suff ered from a ST-segment elevation myo-
cardial infarction (STEMI). The presence of Metabolic Syndrome in viscerally obese subjects was 
associated with increased maximum vessel wall thickness of the carotid bulb approaching the 
level observed in STEMI patients. Furthermore, the imaging technique was shown to be able 
to discriminate groups with varying cardiovascular risk profi les using both focal and global 
measures for the assessment of atherosclerosis.
Visceral obesity and the accompanying metabolic disturbances and low-grade systemic infl am-
mation, as refl ected by C-Reactive Protein (CRP) levels, are interrelated and have both been 
shown to associate with an increased risk of cardiovascular disease. In chapter 5 after exploring 
the relation between CRP and visceral obesity, we evaluated the relation between CRP and 
carotid atherosclerosis in male subjects without type 2 diabetes and manifest cardiovascular 
disease. A signifi cant correlation was shown between visceral obesity and serum CRP levels. 
Furthermore, elevated CRP levels were shown to associate with signifi cantly increased maxi-
mum vessel wall thickness independent of visceral obesity and of MRI measured adipose tissue 
distribution, both in the common carotid artery and the carotid bulb.  
To focus on the in vivo interactions between infl ammation and lipoprotein metabolism with 
regard to atherosclerosis, serum apolipoprotein CI (ApoCI) concentrations were evaluated in 
viscerally obese subjects. ApoCI infl uences many proteins involved in the remodelling of lipo-
proteins in plasma. An important role of ApoCI in the modulation of the infl ammatory response 
has been shown both in vitro and in mice. Furthermore, recent experimental data have revealed 
that ApoCI augments the development of atherosclerosis in the setting of chronic infl ammation 
in mice. In chapter 6, we demonstrated a signifi cant interaction between CRP levels and ApoCI 
concentrations in determining carotid artery atherosclerosis in male subjects with visceral 
obesity. More specifi cally, we observed signifi cantly increased maximum vessel wall thickness 
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in the carotid artery in subjects with both systemic infl ammation and ApoCI concentrations 
above the median. These observations confi rm in vivo, in human subjects, previous proof of 
principle experiments reported in mouse models of atherosclerosis.
In this section, the presence of Metabolic Syndrome in viscerally obese subjects was shown 
to associate with increased focal atherosclerotic changes in the carotid artery. A close associa-
tion between visceral obesity and systemic infl ammation was demonstrated. Furthermore, the 
observations demonstrated an impact of CRP on the atherosclerotic disease burden indepen-
dent of visceral obesity. CRP was also shown to aff ect atherosclerosis through interactions with 
lipoprotein metabolism. These observations support the crucial role of infl ammation in the 
atherosclerotic process. 
PART III: VISCERAL OBESITY AND SYSTEMIC INFLAMMATION AS 
THERAPEUTIC TARGETS IN ATHEROSCLEROSIS
In this section, the infl uence of rosiglitazone in addition to intensive lifestyle treatment com-
pared to lifestyle treatment alone, on the progression of atherosclerosis and the cardiovascular 
risk profi le was evaluated in the setting of a double blinded, placebo controlled, randomized 
clinical trial. Viscerally obese male subjects with the metabolic syndrome (i.e. clustering of car-
diovascular risk factors) and an elevated basal infl ammatory status were included in this study. 
The patients were without established cardiovascular disease and type2 diabetes mellitus and 
were treated for a period of 52 weeks. The aim of this study was to assess whether rosiglitazone 
therapy in addition to intensive lifestyle treatment compared to lifestyle treatment alone could 
prevent the progression of carotid atherosclerosis in men with visceral obesity and elevated 
CRP levels (chapter 7). Another endpoint of the study was to evaluate whether rosiglitazone 
therapy in addition to intensive lifestyle treatment compared to lifestyle treatment alone could 
improve circulating progenitor cell profi les in men with visceral obesity and elevated CRP levels 
(chapter 8). Signifi cant improvements in cardiovascular risk factors were seen after the 52 
weeks of treatment in response to eff ective lifestyle treatment. Both anthropometric measures 
and blood pressure were reduced signifi cantly at the end of the treatment period. Increased 
reductions in CRP levels were seen in patients treated with rosiglitazone as hypothesized. The 
addition of rosiglitazone to lifestyle therapy did not prevent the progression of atherosclerosis 
in these patients.  However, signifi cant increases in CD34+ cell counts were seen in response to 
rosiglitazone therapy in addition to lifestyle treatment. CD34+ stem cells are known to be most 
closely related to cardiovascular risk compared with other circulating endothelial progenitor 






Taken together, the observations of this study underline the impressive impact of lifestyle 
therapy on the cardiovascular risk profi le. The addition of rosiglitazone treatment to lifestyle 
therapy does not prevent the progression of carotid atherosclerosis, but is accompanied with a 
signifi cant increase in CD34+ circulating stem cells.  
FUTURE PERSPECTIVES
This thesis has explored several aspects of the relation between visceral obesity and the 
accompanying metabolic disturbances, systemic infl ammation and the atherosclerotic process. 
Nonetheless, other aspects should be further evaluated in future studies. Magnetic resonance 
vascular imaging, although accurate and reproducible in assessing vessel wall characteristics, 
requires further validation with regard to ultimate cardiovascular outcome data. Furthermore, 
contrast enhanced plaque characterisation may provide additional valuable information in 
future vascular phenotyping and interventional studies. 
The identifi cation of patients at risk of developing atherosclerotic cardiovascular disease 
remains an essential point in the primary prevention setting. Further phenotyping of visceral 
obese subjects with regard to the specifi c infl ammatory response in relation with adipose tis-
sue distribution by evaluating the cytokine profi les may prove useful in further understanding 
of the infl ammatory response in these individuals. 
Regarding the circulating progenitor cells, assessments of the functional properties of these 
cells may prove useful in understanding the role of endothelial repair mechanism in the 
atherosclerotic process and could contribute to the early identifi cation of subjects at risk of 
developing cardiovascular disease. 
Finally, with regard to the treatment strategy in visceral obesity, our observations demonstrate 
an impressive impact of lifestyle therapy. These observations, however, concern only male 
patients and will have to be confi rmed in female population. Furthermore, additional inhibition 
of the systemic infl ammatory response in visceral obesity may be of importance in limiting or 
restoring of the endothelial function. Evaluation of endothelial functional properties in future 
studies may provide valuable information in this regard.
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SAMENVAT TING EN CONCLUSIES
In dit proefschrift werd de invloed van viscerale obesitas en daarmee samenhangende meta-
bole ontregelingen, en het systemische infl ammatie op het atherosclerotische proces bestu-
deerd. Er werd gekozen voor een aanpak in drie stappen. Allereerst werd de beeldvorming van 
de vaatwand met behulp van de “black-blood” techniek op een 3 Tesla MRI ontwikkeld. In de 
tweede plaats, werd de 3T MRI techniek gebruikt in het fenotyperen van patiënten met viscerale 
obesitas. Tenslotte, werd de behandeling van viscerale obesitas en systemische infl ammatie 
door middel van leefstijl begeleiding gecombineerd met rosiglitazon vergeleken met leefstijl 
begeleiding alleen in een gerandomiseerde klinische studie. De progressie van atherosclerose 
werd geëvalueerd ook in deze studie met behulp van de 3T vaatwand MRI. 
DEEL I: 3 TESLA MRI VAATWAND BEELDVORMING
Op een 3 Tesla MRI systeem werd een vaatwand-imaging techniek ontwikkeld voor de beeld-
vorming van arteria carotis. De reproduceerbaarheid van de metingen van de vaatwand door 
MRI werd geëvalueerd zoals beschreven in hoofdstuk 2. Er werd een hoge reproduceerbaar-
heid gezien voor zowel de metingen van de vaatwand oppervlakte als de metingen van de 
vaatwanddikte. Vaatwand oppervlakte is een globale refl ectie van de ernst van de aanwezige 
atherosclerose, terwijl vaatwanddikte een refl ectie is van de locale atherosclerotische verande-
ringen.
Vaatwandmetingen verkregen met behulp van de MRI werden vervolgens vergeleken met 
echografi sche vaatwand metingen (intima media dikte (IMT)) van de arteria carotis. In hoofd-
stuk 3 werd de goede overeenkomst tussen beide technieken in de beoordeling van vasculaire 
en luminale dimensies van de arteria carotis beschreven. Verder werd in dit hoofdstuk het ver-
mogen van de MRI techniek om vaatwandkarakteristieken te onderscheiden tussen patiënten 
met verschillende cardiovasculaire risicoprofi elen aangetoond. 
Samenvattend is de 3 Tesla vaatwand MRI techniek van de arteria carotis een reproduceerbare 
meting. Het kan patiënten met verschillend cardiovasculair risico profi el onderscheidden en 
zich meten met gevestigde echografi sche vaatwandmetingen. 
DEEL II: HET FENOTYPEREN VAN VISCERALE OBESITAS
Viscerale obesitas en de daarmee samenhangende metabole ontregelingen worden bieden 
















ziekten. In hoofdstuk 4 werd de atherosclerotische gevolgen van de aanwezigheid van meta-
bole ontregelingen in de setting van viscerale obesitas bestudeerd. De aanwezigheid van het 
metabool syndroom in patiënten met viscerale obesitas was geassocieerd met een grotere 
vaatwanddikte in de arteria carotis in vergelijking met patiënten met viscerale obesiats alleen. 
Zowel viscerale obesitas als systemische infl ammatie zijn geassocieerd met een verhoogd risico 
op het ontwikkelen van cardiovasculaire events, ook in de afwezigheid van type 2 diabetes 
mellitus. In hoofdstuk 5 werd de verhouding tussen viscerale obesitas en systemische infl am-
matie, beoordeeld door het serum c-reactive protein (CRP) gehalte, bestudeerd in relatie tot 
atherosclerotische veranderingen van arteria carotis. Een signifi cante correlatie werd geobser-
veerd tussen viscerale obesitas en CRP. Tevens was een verhoogd CRP gehalte geassocieerd 
met signifi cant hogere maximale vaatwanddikte, onafhankelijk van de invloed van viscerale 
obesitas en de door MRI beoordeelde vetdistributie. 
Om de in vivo interactie tussen infl ammatie en het vetmetabolisme, in relatie tot atherosclerose 
te bestuderen, werden serum apolipoprotein CI (ApoCI) concentraties geëvalueerd in patiënten 
met viscerale obesitas. ApoCI beïnvloedt veel eiwitten die betrokken zijn in de remodelling van 
plasma lipoproteinen. Een modulerend eff ect van ApoCI op de infl ammatoire response is ook 
aangetoond zowel in vitro als in muismodellen. Recente studies hebben aangetoond dat ApoCI 
bevordert de progressie van atherosclerose in de aanwezigheid van chronische infl ammatie. In 
hoofdstuk 6, werd en signifi cante interactie geobserveerd tussen CRP en ApoCI concentraties 
in het bepalen van de atherosclerose van arteria carotis. Patiënten met zowel een verhoogde 
CRP als ApoCI concentratie hadden een grotere vaatwanddikte in de arteria carotis. 
Samenvattend werd in deel II een relatie aangetoond tussen de aanwezigheid van metabole 
ontregelingen en een grotere vaatwanddikte van arteria carotis.  Een verhoogde serum CRP 
waarde bleek gepaard te gaan met een toegenomen dikte van de vaatwand onafhankelijk van 
viscerale obesitas. Ook werd er een interactie gevonden tussen CRP en ApoCI als determinant 
van atherosclerose van de arteria carotis. Deze bevindingen bevestigen de belangrijke associ-
atie van infl ammatie met het atherosclerotische proces. 
DEEL III: VISCERALE OBESITAS EN SYSTEMISCHE INFLAMMATIE ALS 
THERAPEUTISCHE TARGETS IN ATHEROSCLEROSE
In het laatste onderdeel van dit proefschrift lag de focus op de behandeling van viscerale 
obesitas en systemische infl ammatie. Het doel van de behandeling was remming van de 
progressie van atherosclerose. In een dubbel blinde, placebo gecontroleerde, gerando-
miseerde klinische studie, werd de invloed van behandeling met rosiglitazon samen met 
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leefstijl begeleiding vergeleken met leefstijl begeleiding alleen. De behandeling duurde 52 
weken. De geincludeerde patiënten waren mannen met viscerale obesitas en een verhoogd 
serum CRP gehalte. De patiënten hadden geen type 2 diabetes mellitus of klinisch manifeste 
cardiovasculaire ziekten. De eff ecten van de behandeling gemeten als de remming van de 
progressie van atherosclerose zijn beschreven in hoofdstuk 7. Een ander eindpunt van de stu-
die was de bestudering van de invloed van de behandeling op circulerende stamcelprofi elen 
(hoofdstuk 8). Eff ectieve leefstijlbegeleiding resulteerde in een signifi cante verbetering van 
het cardiovasculaire risicoprofi el van de patiënten. Er werden signifi cante afnames gezien van 
de buikomvang, lichaamsgewicht en bloeddruk na 52 weken behandeling. Bij patiënten die 
behandeld werden met rosiglitazon daalde het serum CRP gehalte meer dan in de placebo 
groep. Toevoeging van rosiglitazon aan de behandeling had geen toegevoegde waarde met 
betrekking tot de remming van de progressie van atherosclerose. Het endotheliale stamcelpro-
fi el werd wel beïnvloed door rosiglitazon behandeling. Circulerende CD34+ stamcellen stegen 
signifi cant meer in de met rosiglitazon behandelde groep. 
Samenvattend werd gevonden dat eff ectieve leefstijlbegeleiding het cardiovasculaire risico-
profi el sterk verbeterde. Toevoeging van rosiglitazon aan deze behandeling had geen eff ect op 
het remmen van de progressie van atherosclerose in de arteria carotis, maar wel op circulerende 
CD34+ stamcellen.
TOEKOMSTPERSPECTIEVEN
Met de studies beschreven in dit proefschrift, werd geprobeerd om meer inzicht te verkrijgen in 
de relatie tussen viscerale obesitas en de daarmee samenhangende metabole ontregelingen, 
systemische infl ammatie en het atherosclerotische proces. De vasculaire MRI techniek toege-
past in de magnetische veldsterkte van 3 Tesla dient verder geëvalueerd te worden met betrek-
king tot uiteindelijke cardiovasculaire klinische eindpunten. Het gebruik van contrast middelen 
in de 3T veldsterkte zou ook tot verdere verbetering van de beeldkwaliteit kunnen leiden bij de 
imaging van de vaatwand en tevens kunnen bijdragen aan vaatwand (plaque) karacterisatie. 
Het identifi ceren van patiënten met een verhoogd risico op het ontwikkelen van atheroscleroti-
sche cardiovasculaire ziekten blijft een belangrijk aandachtspunt binnen de primaire preventie 
setting en de rol van imaging in dit proces verdient verdere aandacht. Met betrekking tot het 
stamcelprofi el bij de fenotypering van viscerale obesitas, zou de evaluatie van functionele 
eigenschappen van deze cellen additionele informatie kunnen verschaff en over de endotheli-
















Ten slotte, de resultaten van dit proefschrift bevestigen de grote eff ecten van een eff ectieve 
leefstijlbegeleiding op het cardiovasculaire risicoprofi el. Deze observaties betroff en echter 
alleen mannelijke patiënten en moeten ook bevestigd worden in vrouwelijke populaties. 
Onderdrukking van de infl ammatoire response in patiënten met viscerale obesitas zou gunstige 
eff ecten kunnen hebben op endotheelfunctie en progressie van atherosclerose in patiënten 
met viscerale obesitas. Dit kan een aangrijpingspunt zijn voor de behandeling van atheroscle-
rose en het voorkomen van cardiovasculaire ziekten in patiënten met viscerale obesitas. 
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